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ABSTRACT 
 
 
Chronic myeloid leukemia (CML) is a hematologic malignancy that originates from 
pluripotent hematopoietic stem cells. The genetic abnormality underlying this disease, 
as well as a subtype of acute lymphoblastic leukemia (ALL), is a translocation 
between chromosomes 9 and 22, which leads to the formation of the Philadelphia (Ph) 
chromosome and the oncogenic BCR-ABL1 fusion protein. This oncoprotein induces 
cell proliferation, causes abnormal migration, and reduces apoptosis. Targeted 
inhibition of the BCR-ABL1 protein with imatinib and other specific tyrosine kinase 
inhibitors (TKIs) has revolutionized CML treatment and is currently regarded as the 
gold standard of targeted cancer therapy. In this doctoral thesis, different 
methodological approaches were used to characterize aberrant signaling activities in 
leukemic and normal cells with the ultimate aim of isolating novel prognostic markers 
for predicting TKI therapy outcome. 
 
First, the molecular mechanism of the disease was investigated in an ALL patient 
with a translocation between chromosomes 1 and 9. Cytogenetic characterization 
showed involvement of the ABL1 gene fused to an unknown gene. The RCSD1 gene 
was selected as a candidate translocation partner and subsequent molecular dissection 
confirmed a RCSD1-ABL1 fusion. This novel fusion gene predicts sensitivity to TKI 
therapy in ALL patients. 
 
Second, several phosphoproteins related to immune cell function were analyzed both 
from the diagnostic phase CML patients and from patients under TKI therapy in order 
to reveal distinct signaling patterns associated with therapy responses. A single cell 
phosphoprotein method based on multiparameter flow cytometry was used to analyze 
phosphoprotein levels in different cell populations. The responsiveness of myeloid 
cells to ex vivo cytokine stimulation in diagnostic-phase patients was low, but was 
normalized in TKI-treated patients. In general, the blood leukocyte subsets responded 
normally to various cytokine stimulations, which indicated a non-immunosuppressive 
role for TKIs. This project also led to the development of a software–assisted analysis 
program, which can conduct the whole range of flow cytometry data analysis, thereby 
diminishing the effort needed for manual cell population gating and interpretation. 
 
Lastly, biomarkers for therapy response were identified by analyzing aberrant 
signaling activities in leukemic cells collected at the time of diagnosis. The analysis 
was based on a phosphoproteomic array measuring phosphorylation of 46 different 
kinase targets. Several proteins had aberrant phosphorylation levels in patients with a 
poor therapy outcome − pSTAT5b being the most prominent. These biomarkers could 
be useful in guiding therapy selection at the time of diagnosis.  
 
In conclusion, the findings imply that TKI therapy responses can be linked to certain 
biological markers, which can possibly be utilized in clinical applications in the 
future. 
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ABBREVIATIONS 
 
 
A488 Alexa488    
ABL1  Abelson murine leukemia viral oncogene homolog 1 gene 
AML Acute myeloid leukemia   
ALL Acute lymphoblastic leukemia  
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ERK Extracellular signal- regulated kinase   
EUTOS European treatment and outcome Study 
FACS Fluorescent-activated cell sorting  
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FSC Forward scatter   
GIST Gastrointestinal tumor   
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MRD Minimal residual disease   
NSCLC Non-small-cell lung cancer   
PB Peripheral blood   
PBS Phosphate buffered saline   
PCR Polymerase chain reaction   
PDGFR Platelet-derived growth factor receptor  
PE Phycoerythrin   
PE-Cy7 PE-Cyanine7   
PerCP Peridinin chlorophyll protein  
Ph Philadelphia chromosome   
PKC Protein kinase C   
PLCγ-1 Phospholipase C γ-1   
RQ-PCR Real time quantitative polymerase chain reaction 
SCNP Single-cell network profiling  
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SSC Side scatter    
STAT Signal transducer and activator of transcription 
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TKI Tyrosine kinase inhibitor   
Treg Regulatory T cell   
VEGFR Vascular endothelial growth factor receptor 
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1  INTRODUCTION 
 
Cancer is a heterogeneous group of diseases characterized by the accumulation of 
genetic changes in tumor cells giving them a growth advantage over normal cells and 
resulting in uncontrollable cell proliferation. Leukemia is a type of cancer that affects 
leukocytes of the blood or bone marrow (BM). The expanding leukocytes are usually 
immature, based on their developmental stage. Leukemias are classified as either 
myeloid or lymphatic by their cell lineage, as well as acute or chronic by the nature of 
progression. 
 
Protein kinases regulate cellular signaling cascades as a response to extracellular and 
intracellular stimuli, thus controlling cell survival, proliferation, cell growth and other 
cellular processes. Kinases function by transferring phosphate molecules to their 
substrates in a process called phosphorylation. They can be divided into cell surface 
receptor and intracellular non-receptor kinases as well as tyrosine and 
serine/threonine kinases based on substrate specificity. Deregulated kinase signaling 
due to various mechanisms can disrupt cell homeostasis and lead to cancer. At 
present, the cause of pathogenesis of many cancers is known to be aberrant, 
abnormally controlled kinase signaling, which has guided the development of targeted 
cancer therapies. 
 
Chronic myeloid leukemia (CML) is one of the most studied types of cancer, and has 
for decades been regarded as a model disease in cancer research. The pathogenesis of 
CML and a subtype of acute lymphoblastic leukemia (ALL) is characterized by the 
formation of the Philadelphia (Ph) chromosome, a reciprocal translocation between 
chromosomes 9 and 22 t(9;22)(q34;q11) occurring in hematopoietic stem cells. The 
Ph chromosome contains an oncogenic BCR-ABL1 fusion gene that encodes for a 
constitutively active BCR-ABL1 fusion protein that is responsible for increased 
proliferation, abnormal migration, and reduced apoptosis. 
 
Imatinib (Glivec, Novartis Pharma) was the first tyrosine kinase inhibitor (TKI) 
developed specifically to combat the increased tyrosine activity of the BCR-ABL1, 
and has since been considered the model example for targeted cancer therapy. 
Imatinib renders the kinase domain (KD) of BCR-ABL1 dysfunctional, thereby 
inhibiting the oncogenic signaling that protects cancerous cells from apoptosis. Due to 
major improvements in the therapy responses after introduction of imatinib, CML is 
now regarded as a chronic, manageable disease. However, some patients develop 
resistance to imatinib, resulting in disease relapse. The majority of resistance can be 
explained by the occurrence of point mutations in the KD of BCR-ABL1, which 
prevents efficient binding of imatinib. To tackle this problem, a series of second and 
third generation TKIs have been developed that have shown promising results with 
many of these patients. Some therapy failures are not associated with mutations but 
other defined resistance mechanisms. 
 
The presence of BCR-ABL1 fusion gene transcript in blood or BM is the basis for 
measuring therapy response for Ph+ leukemias. In the TKI era, the polymerase chain 
reaction (PCR) has provided the most sensitive method for evaluating therapy 
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responses, as well as in detecting point mutations. A notable area of research deals 
with defining valid biomarkers for the guidance in selecting the optimal TKI therapy. 
The ability to find these candidate markers are based on genetic, proteomic, and 
immunological factors. Despite the good responses obtained with TKIs, CML is not 
regarded as a curable disease at this point in time. Therefore, in addition to BCR-
ABL1, new therapy targets maybe required in the cure for CML patients. 
 
This study was aimed to understand the molecular background of a distinct form of 
Ph-negative ALL disease, which was empirically shown to be sensitive for TKI 
therapy. In addition, different methodological approaches were used to characterize 
cellular signaling patterns in leukemic and non-leukemic cells in CML patients at 
diagnosis and during TKI therapy and their correlation with therapy responses was 
evaluated. Finally, an automated flow cytometry data analysis program was 
developed to assist time-consuming and laborious flow cytometry data analysis. 
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2  REVIEW OF THE LITERATURE 
 
2.1 Kinase signaling as a therapy target 
2.1.1 Kinase signaling at the molecular level 
   
Protein kinases are a large family of enzymes that are essential for mediating external 
stimuli inside cells. They are divided into serine/threonine kinases (STK) and tyrosine 
kinases (TK) according to their substrate specificity. 1 TKs activate numerous 
signaling pathways that are responsible for cell proliferation, differentiation, 
migration, and metabolic changes. Due to these functions TKs have well-established 
role in many cancers and other proliferative diseases. 2 STKs phosphorylate 
transcription factors, cell cycle regulators cytoplasmic and nuclear effectors, and are 
linked to cancer as well.3 
 
Kinases also fall into two categories according to their location and function inside 
the cell. Receptor kinases are transmembrane proteins with an extracellular ligand-
binding domain. The intracellular domain is responsible for catalytic activity. 
Nonreceptor kinases reside in the cytosol, nucleus, and inner surface of the plasma 
membrane and therefore lack a transmembrane domain. Activity of both types of 
kinases is regulated tightly, so that normal cells in a resting state have low levels of 
phosphorylated residues. 4 
 
The core kinase structure responsible for adenosine triphosphate (ATP) binding is 
highly conserved in eukaryotic kinases 5. This core structure is built from the N-
terminal lobe and a larger C-terminal lobe connected with a hinge region. ATP binds 
to a cleft between the two lobes, while substrate binds to the C-terminal lobe. The 
adenine ring of ATP forms hydrogen bonds with the hinge region and the glycine 
loop in the N-terminal lobe binds to the triphosphate. An activation loop in the C-
terminal lobe includes conserved DFG and APE sequences. In the active 
conformation, the activation loop is usually phosphorylated and in the catalytically 
active state. The inactive state conformation of the activation loop has a higher 
variation between kinases and blocks the substrate-binding site. 6 
 
In their inactive form, receptor TKs are monomeric or dimeric and unphosphorylated. 
Binding of a specific ligand to the extracellular domain triggers receptor dimerization, 
stabilization of the dimer, and transphosphorylation of tyrosine residues in the 
activation loop. This generates recruitment sites for downstream signaling molecules 
that have phosphotyrosine recognitions domains. 7 These include either the SRC 
homology-2 (SH2) domain or the phosphotyrosine binding (PTB) domain. 8 The 
tyrosine phosphorylation of the receptor kinases also activates the enzymatic TK 
activity. 7 In addition to the activation loop, a subset of receptor TKs have a 
juxtamembrane region in the C-terminal tail. This region has autoinhibitory 
properties, which prevent the TK function by interacting with the KD in the inactive 
state. 9,10   
 
Intracellular kinases are regulated and maintained inactive trough interactions with 
inhibitory proteins, lipids, and autoinhibitory mechanisms. Activation is mediated by 
intracellular signals such as dissociation of inhibitors, by interaction with 
transmembrane receptors, and by phosphorylation by other kinases.4  
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2.1.2 Kinase inhibition in cancer therapy 
 
Since the discovery of the first oncogenic kinase, v-SRC in 1970, 11 deregulated 
kinase signaling has been linked to pathogenesis of cancer. In addition to cancers, 
deregulated kinases are associated with various immunological, metabolic, 
neurological, and infectious diseases. Despite the characterization of this clear 
connection between molecular level defects and disease, not much effort was initially 
made to target kinases. 12 Eventually, the discovery of staurosporine, a protein kinase 
C (PKC) inhibitor naturally produced by Streptomyces, 13 led to activation of research 
in the field of kinase inhibitors.  
 
Small molecule kinase inhibitors are today the most popular type of cancer drug under 
development in the pharmaceutical industry. The discovery of new kinase inhibitors 
has benefited enormously from rational drug design through crystallographic 
techniques. The assessment of kinase inhibitor selectivity has also improved with 
modern proteomic approaches. This kind of progress made in the technologies of 
inhibitor development has ensured fast discovery of selective small molecule 
inhibitors with optimal pharmacological properties.   
 
In 2010, 149 kinase inhibitors were being tested in clinical trials (Fig. 1), 14 and by 
2012, 13 small-molecule kinase inhibitors were approved for treatment of cancer by 
the U.S. Food and Drug Administration (FDA) (Table 1). 15 The targets of these 
inhibitors included ABL1 (BCR-ABL1), platelet-derived growth factor receptor 
(PDGFR), KIT kinases, as well as the endothelial growth factor receptor (EGFR) and 
vascular endothelial growth factor receptor (VEGFR) families.  16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Kinase targets in clinical trials in 2010. Reprinted with permission. © 2010 
Nature Publishing Group.14 
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Table 1. FDA-approved small molecule kinase inhibitors for clinical use. Adjusted 
from Dar AC & Shokat KM 201115 and Jänne PA et al. 2009 16 
 
CML, chronic myeloid leukemia; GIST, gastrointestinal tumor; HES, 
hypereosinophilic syndrome; ALL, acute lymphoblastic leukemia; NSCLC, non-small-
cell lung cancer; PDGFR, platelet-derived growth factor receptor; EGFR, epidermal 
growth factor receptor; C-KIT, CD117, mast/stem cell growth factor receptor; 
ERBB2, human epidermal growth factor receptor 2 (HER2); JAK, janus kinase; 
BRAF, serine/threonine kinase encoded by v-RAF murine sarcoma viral oncogene 
homolog B, *also for dermatofibrosarcoma protuberans, systemic mastocytosis. 
 
 
 
 
 
Inhibitor Main kinase targets Indication 
FDA approval 
year 
Imatinib BCR-ABL1, C-KIT, PDGFR 
CML, Ph+ALL, 
GIST, HES* 2001 
Gefitinib EGFR, ERBB2, HER4 NSCLC 2003 
Sorafenib C-KIT, PDGFR, VEGFR  
Renal cancer, 
hepatocellular 
carcinoma 
2005 
Erlotinib EGFR, ERBB2  
NSCLC, pancreas 
cancer 2005 
Sunitinib C-KIT, PDGFR, VEGFR 
Renal cancer, 
imatinib-refractory 
GIST, pancreatic 
neuroendocrine 
tumor 
2006 
Dasatinib 
BCR-ABL1, SRC 
family 
 
CML and Ph+ 
ALL  2006 
Nilotinib 
BCR-ABL, 
PDGFR, C-KIT 
 
CML 
 2007 
Lapatinib ERBB2, EGFR HER2+ breast cancer 2007 
Pazopanib 
VEGFR, PDGFR, 
C-KIT 
 
Renal cell 
carcinoma, soft 
tissue carcinoma 
2009 
Vemurafenib B-RAF Melanoma 2011 
Ruxolitinib JAK Myelofibrosis 2011 
Axitinib 
VEGFR, PDGFR, 
C-KIT 
 
Renal cell 
carcinoma 2012 
Bosutinib BCR-ABL1, SRC  
CML resistant to 
other therapies 2012 
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2.1.2.1 Types of kinase targets 
 
The efficacy of kinase inhibition is most prominent when cancer is driven by a single 
alteration in a kinase essential for cancer cell proliferation and survival. This is 
termed ‘oncogene addiction’ and renders cancer cells susceptible to targeted 
inhibition of the oncogenic kinase. 17,18 Another type of kinase inhibition targets 
kinases that are encoded by a pair of synthetic lethal genes, which are lethal when 
both genes are mutated. 19 When only one gene of the pair is mutated, targeting of the 
nonmutated kinase would result in a synthetic lethal phenotype. 20 These kinases are 
usually situated downstream of key elements in the oncogenic signaling pathways and 
are important for cancer cell survival and proliferation. A third class of kinase targets 
is essential for maintaining the tumor microenvironment or its kinases are expressed 
within the tumor itself and are required for formation and maintenance of the tumor. 
At present, the first type of kinases – those based on kinase addiction – are the most 
potent targets for kinase inhibition. These kinases are usually highly transforming, 
easily identifiable by DNA sequencing, and the inhibitor screening is somewhat 
straightforward during optimization. 12 
 
2.1.3 Kinase inhibitors  
 
The strategy underlying the use of kinase inhibitors is to prevent transfer of the 
terminal phosphate of ATP to tyrosine, serine, or threonine residues of the substrate 
molecule. The majority of kinase inhibitors are ATP competitive and small-weight 
molecules. 12 Type I inhibitors preferentially bind to the active conformation of the 
kinase and are the most common type of ATP competitive inhibitors. They mimic the 
hydrogen bonds normally formed between the adenine ring and the hinge region in 
the core structure. 21,22 Type II inhibitors are characterized by their binding to the 
inactive conformation of the kinase. In the inactive conformation, the activation loop 
DFG sequence points outward, exposing the hydrophobic site adjacent to the ATP 
binding site. Examples of these types of inhibitors are imatinib and nilotinib, which 
inhibit BCR-ABL1 but also several other kinases such as C-KIT. 23 The crystal 
structure of the complex formed by this type inhibitor and the kinase was first 
revealed with imatinib bound to ABL1. 24 The type II kinase inhibitor binding site is 
less conserved and therefore has a higher potential for specific inhibition than do the 
type I inhibitors. 21,25  
 
A completely different mechanism for targeting kinases is taken by allosteric 
inhibitors, which are uncompetitive with ATP binding. Non-ATP competitive 
inhibitors are also called type III inhibitors. These bind to an allosteric site, which can 
bind regulators that affect enzyme activity. The binding sites show high variation 
between different kinases, resulting in the observation of high selectivity with 
allosteric inhibitors. 12,26 Covalent inhibitors are the fourth type of kinase inhibitors; 
these form irreversible covalent bonds with the active site. The covalent bond is 
usually formed between the inhibitor and a cysteine residue, resulting in blockage of 
the ATP binding site. 27 The advantage of these inhibitors is the possibility of having 
a short half-life, combined with reduced dosing. However, concerns have been raised 
regarding the adverse effects caused by off-target irreversible complexes formed by 
covalent inhibitors. 28 
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2.1.4 Selectivity of kinase inhibitors 
 
The goal of developing kinase inhibitors is to achieve the highest possible selectivity 
against a specific kinase. However, many clinically approved inhibitors inhibit a 
number of other kinases. 29 The challenge for the development of specificity comes 
not only from the 518 kinases of the human kinome, 30 but also from large number of 
other purine-binding proteins coded by the human genome. 31 The advantage of 
selective kinase inhibitors is their smaller likelihood of toxicity, whereas inhibitors 
with a broader target spectrum can be utilized with multiple indications and can 
simultaneously affect many cellular processes associated with the tumor. 16  
 
Several methods are available for assessment of the in vitro selectivity of inhibitors. 
These assays are based on measurement of the phosphorylation, dissociation constant, 
and melting temperature of the inhibited kinase. 32 At the moment, selectivity data are 
accessible for 178 commercially available kinase inhibitors that function against 300 
kinases. 33 The selectivity of kinase inhibitors should also be evaluated at the cellular 
level, because in vitro results do not always apply in vivo. A popular system for 
studying kinase inhibitor selectivity at the cellular level is the murine interleukin-3 
(IL-3) dependent pro-B cell line (BA/F3), which can be transformed with oncogenes 
and in which the ability of kinase inhibitor to induce specific cell death can be 
discriminated from non-specific cell death by addition of IL-3. 34 A chemical 
genomics method utilizes yeast cells expressing engineered kinases, in which specific 
kinase inhibition is observed as a transcriptional change.35 A high throughput assay 
uses HEK-293 cells and fluorescence resonance energy transfer (FRET), where kinase 
inhibitor binding causes a conformational change in the kinase and elicits a detectable 
signal. 36 The transition from the cell level to the organismal level might also affect 
the efficacy of a kinase inhibitor due to various factors such as differential kinase 
expression and drug distribution in different tissues. 32  
 
2.1.5 Factors behind the sensitivity of kinase inhibition 
 
An increasing challenge in the clinic is to overcome resistance to kinase inhibition 
therapy. De novo resistance describes a situation whereby the response to an inhibitor 
is not achieved in the initial treatment. The reasons behind this can be lack of 
addiction to the kinase inhibited and altered drug metabolism, which are regulated by 
germ line polymorphisms. Acquired resistance occurs when the response to a 
particular kinase inhibitor is lost during the course of the treatment. 16 The mechanism 
of acquired resistance can be assessed with genomic analysis of samples from kinase 
inhibitor resistant patients. Long-term cancer cell culture with a kinase inhibitor can 
result in the development of resistant clones, which can then be used to reveal the 
mechanism underlying resistance. 37 
 
The major cause for acquired resistance is point mutations in the KD area. A common 
point mutation results in replacement of the gatekeeper residue threonine into a larger 
hydrophobic residue. This gatekeeper residue controls the access of kinase inhibitors 
to the hydrophobic pocket deep within the active site. Point mutations that result in 
amino acid residues with bulky side chains at this particular site prevent the binding 
of kinase inhibitors, while catalytic activity remains or is even stimulated. 38 Another 
example of inhibitor resistance mechanism involves amplification of the MET gene in 
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EGFR-activated cancers. MET signaling activates survival signaling in a fashion 
similar to that seen with EGFR signaling, and renders EGFR inhibition ineffective. 
This is regarded as a compensatory circuit pathway. 39 Elevated levels of the MET 
ligand hepatocyte growth factor (HGF) have a similar effect to that seen with 
amplification of the MET gene. 40  
 
Acquired resistance involving mutations in the KD has been overcome by rational 
design of second-generation inhibitors that are able to inhibit the mutated kinase. 
Combination therapies, instead of monotherapies, are also an ideal option for 
treatment of cancers, in which compensatory signaling pathways have developed as a 
survival mechanism. Genetic screening at the time of diagnosis for polymorphisms 
known to affect kinase inhibitor efficacy can possibly be used in the future to guide 
therapy selection and dosage. 16 
 
2.2 Chronic myeloid leukemia as a model disease of kinase inhibition therapy 
2.2.1 The Ph chromosome behind the pathogenesis of CML 
 
Chronic myeloid leukemia is one of the most extensively studied human 
malignancies. The cause for the disease was found in 1960, 41 when the Ph 
chromosome was discovered, and reciprocal translocation between chromosomes 9 
and 22 was revealed in 1973. 42 In the 1980s, the molecular mechanism of the disease 
was identified when the t(9:22) translocation was shown to involve the Abelson 
murine leukemia viral oncogene homolog 1 gene (ABL1) from chromosome 9 43 and a 
breakpoint cluster region (BCR) from chromosome 22 44 (Fig. 2). Subsequently, BCR-
ABL1 fusion transcripts were discovered in patients with CML 45,46, which led to 
identification of the 210 kD-sized BCR-ABL1 fusion protein 47 that showed an 
enhanced tyrosine kinase activity compared to the normal ABL1 protein. 48 The 
transforming potential of BCR-ABL1 was first shown in cell lines and mouse BM 
cells. 49,50 The oncogenic transformation capability of the BCR-ABL1 fusion protein 
was later confirmed when retrovirally-infected hematopoietic stem cells expressing 
BCR-ABL1 were able to induce a CML-like disease in mice. 51-53 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Formation of the Philadelphia chromosome in a reciprocal translocation 
between chromosomes 9 and 22, resulting in the BCR-ABL1 fusion gene. Modified 
from Hazlehurst et al. 2009. 54 
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2.2.2 The BCR-ABL1 fusion gene 
 
The BCR-ABL1 protein exists in a few different-sized isoforms, depending on the site 
of the breaking point in the BCR gene, and these isoforms are associated with specific 
types of leukemia (Fig. 3). In the majority of cases of CML, and in one third of Ph+ 
ALL, the BCR breaking point is situated between exons 12 to 16 (formerly b1-b5) 
and therefore this is referred to as the major breaking point area (M-BCR). The 
resulting b2a2 and b3a2 mRNAs are translated into p210 protein. The rest of the Ph+ 
ALL cases are comprised of a BCR-ABL1 sized p190 and encode an e1a2 mRNA 
resulting from the minor BCR (m-BCR) area. This type of isoform is rarely associated 
with CML. 55 The breaking point in the exon 19 micro-BCR (µ-BCR) results in a 
p230 isoform, which is associated with a rare neutrophilic CML. 56  
  
 
Figure 3. Genomic structure of the BCR gene, showing three different breaking point 
sites: m-BCR, M-BCR and µ-BCR and ABL1 gene with a breaking point at a constant 
site in the upper level of the figure. The lower level of the figure represents different 
BCR-ABL1 mRNAs with corresponding protein sizes. Modified from Hazlehurst et al.  
2009. 54 
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2.2.3 BCR-ABL1 signaling in CML 
 
The normal counterpart of the oncoprotein is ABL1 (also known as c-ABL,), which as 
a TK takes part in multiple signaling pathways that mediate responses to growth 
factors, ionizing radiation, oxidative stress, and integrin stimulation; it is also 
associated with signaling during neuronal development. 57 The subcellular 
localization of ABL1 depends on the cell type; for example, the localization in 
primary hematopoietic cells is mostly cytoplasmic. 58 The localization of ABL1 in the 
nucleus or the cytoplasm is determined by specific signal sequences. 57 In the 
cytoplasm, ABL1 is mostly bound to cytoskeletal F-actin, 59 whereas the myristoyl-
modified protein is associated with the inner surface of the plasma membrane. 60 
Multiple different options exist for ABL1 to localize inside the cell and these reflect 
the variety of its roles inside the cell. These tasks include cell adhesion and motility, 
61 DNA damage responses, 62 responses to microbial infection, 63 and actin 
remodeling. 64 ABL1 contains a special domain structure (SRC homology 3–SRC 
homology 2–tyrosine kinase, SH3-SH2-TK), which gives the protein a high potential 
for signaling capabilities.65  
 
BCR is also a signaling protein, but its function is not well known. It is a 160 kD 
protein with STK activity and has several distinct domains. 66 BCR has GTPase 
activating protein (GAP) activity towards p21rac, 67 which is abundantly expressed in 
human neutrophils and where it plays a role in cytoskeletal organization and 
superoxide production. 68 BCR also negatively regulates WNT signaling pathway 69 
and participates in cellular growth factor receptor trafficking. 70 BCR-deficient mice 
have neutrophils that show abnormal respiratory burst activity in the form of 
increased reactive oxygen metabolite production, which suggests a link between BCR 
function and the cell type affected in CML. 71 
 
The BCR-ABL1 fusion protein has been studied extensively. In contrast to the ABL1, 
the oncogenic BCR-ABL1 is expressed solely in the cytoplasm. 58 Its mechanism of 
action is associated with altered cellular adhesion, activation of mitogenic pathways, 
inhibition of apoptosis, and degradation of physiologically important proteins. 72 The 
signaling potency of the BCR-ABL1 fusion protein is based on its increased diversity 
of protein-binding domains compared with its normal counterpart ABL1. The N-
terminal side of BCR-ABL1 has a coiled-coil (CC) domain (Fig. 4), which is 
important for the oncogenicity of BCR-ABL1; it activates the KD in ABL1. The CC 
domain is also responsible for oligomerization of the fusion protein and it binds to 
actin fibers. Oligomerization of BCR-ABL1 is also suggested as an essential part of 
ABL kinase activation. 73 The second important site in the BCR region is the growth 
factor receptor-bound protein 2 (GRB2)-binding site, which is responsible for 
formation of a protein complex consisting of GRB2, son-of-sevenless (SOS), and 
GRB2-associated binding protein 2 (GAB2). Formation of this complex is dependent 
on autophosphorylation of BCR-ABL1 at Y177, which activates the oncogenic 
signaling cascade associated with activation of RAS and recruitment of SHP2 and 
phosphatidylinositol 3-kinase (PI3K). 74-76 RAS activates the mitogen-activated 
protein kinase (MAPK), which enhances proliferation. The phosphorylation site 
Y1294, located in the ABL KD, along with the SH2 domain, also contributes to 
activation of the RAS pathway, although the mechanism is unclear. 77 PI3K activates 
the AKT pathway, which promotes survival by suppressing activity of forkhead O 
(FOXO) transcription factors, 78 enhances proliferation through SKP2-regulated 
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degradation of p2779, and activates mTOR, leading to enhanced protein translation 
and proliferation. 80,81 Phosphorylation of STAT5 directly by BCR-ABL1, or by 
mediation of JAK2 or HCK, mediates proliferation and survival. 82,83 In CML, the 
primitive progenitor cells have diminished adhesion capability to stromal cells and the 
extracellular matrix of the BM, thus losing their normal regulatory signals provided 
by the environment. 84 This is assumed to be mediated by a low affinity of integrin β1 
to adhesive ligands. 85,86 At a signaling level, this interaction is mediated by an 
interaction between BCR-ABL1 and CBL, CRKL and paxillin. 87,88 BCR-ABL1 also 
induces the expression of growth factors IL-3 and granulocyte-macrophage colony-
stimulating factor (GM-CSF), 89,90 which can have further impacts on the 
pathogenesis of CML.  
 
 
 
 
 
Figure 4. Signaling pathways induced by the p210 BCR-ABL1 fusion protein. The 
part originated from the BCR protein includes a coiled-coil (CC) domain, 
serine/threonine kinase (STK), Dbl/CDC24 guanine-nucleotide exchange factor 
homology (DH) domain, and pleckstrin homology (PH) domain. Downstream of the 
breaking point are ABL1-related domains: SRC homology 3 (SH3), SH2, tyrosine 
kinase (TK), proline-rich SH3 binding sites (PP), nuclear localization signals (NLS), 
DNA-binding domain (DBD), actin-binding domain (ABD) and nuclear exporting 
signal (NES). Phosphorylation of tyrosine residues generates docking sites for 
adaptor proteins (purple), which modify activation of multiple signaling pathways 
affecting the cell survival, proliferation, adhesion, and motility.  Modified from Ren 
2005 and O´Hare et al. 2011. 91,92 
 
 
 
 
 
	   21	  
2.2.4 Clinical characteristics and epidemiology of CML 
 
CML is a hematologic malignancy that originates from a transformed pluripotent 
hematopoietic stem cell and affects the myeloid, monocytic and erythroid cells as well 
as platelets and B-cells, 93,94 although the clinical characteristics of CML is expansion 
of granulocytic-series cells in the peripheral blood (PB) (Fig. 5). Increased numbers 
of eosinophils, basophils, and platelets are common, as is anemia. 95 The diagnosis of 
CML is confirmed by the presence of the Ph chromosome and BCR-ABL1 transcripts 
in the blood or BM. 96 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.  Development of CML from BCR-ABL1 positive hematopoietic stem cells 
(HSCs). Self-renewing HSCs differentiate into myeloid cells, such as macrophages 
(Ms), granulocytes (Gs), red blood cells (RBCs) and platelet-producing 
megakaryocytes (MEGs) through common myeloid progenitors (CMPs), common 
granulocyte/macrophage progenitors (GMPs), and megakaryocyte/erythrocyte 
progenitors (MEPs). The lymphoid lineage into T and B cells occurs via a common 
lymphoid progenitor (CLP). Chronic myeloid leukemia (CML) is characterized by 
increased granulopoiesis in the chronic phase. As the disease progresses into the 
blast phase, more primitive cells start to accumulate. Modified from Ren 2005.91 
 
CML is usually diagnosed in the chronic phase, when patients usually lack symptoms 
but might experience fatigue, weight loss, and night sweats. In addition to abnormal 
blood counts, an enlarged spleen is a common finding of CML. CML eventually 
progresses to the accelerated phase, which is characterized by additional 
chromosomal changes, increases in total numbers of leukocytes, basophilia, 
thrombocytopenia, increased spleen size, and the appearance of blasts in the blood or 
BM. The last stage of CML is a blast crisis, which resembles acute leukemia with its 
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large numbers of blasts with either lymphoid or myeloid phenotype. 97 If untreated, 
CML will progress from the chronic phase to death within three to five years. 95  
 
The incidence of CML is 1 to 2 cases per 100 000; 96 however, due to progress made 
in the management of CML in the past decade, the number of patients with chronic 
phase CML is increasing. The common age at diagnosis is around 65 years; 96 it is 
rarely diagnosed in children 98 and the prevalence is slightly higher in men. 99  
 
2.2.5 Ph positive ALL and other ABL1-driven leukemias 
 
The Ph chromosome is the most common cytogenetic abnormality seen in adult ALL 
patients (approximately 20%) and it contributes to 2 % of all pediatric ALL cases.100 
101 Prognosis of Ph+ ALL was very poor prior to the introduction of TKIs as a therapy 
mode. 102  A BCR-ABL1-like gene expression profile has been recently identified 
among Ph negative pediatric ALL patients with B-cell precursor phenotype. This 
BCR-ABL1-like phenotype occurs in 10 % of pediatric ALL patients and is associated 
with a high risk of relapse.  This ALL subtype is hypothesized to benefit from TKI 
therapy103,104. 
 
Other types of fusion genes involving ABL1 have also been characterized (Fig. 6).  
NUP214-ABL1 (TEL-ABL1) is mostly seen in T-cell ALL patients 105. SFPQ-ABL1 106 
and ZMIZ1-ABL1 107 fusions been reported in two separate B-cell ALL patients, and 
EML1-ABL1 once in a T-cell ALL patient. 108 ETV6-ABL1 is more common than 
previously mentioned and is seen in a heterogeneous group of hematologic 
malignancies. 109  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. ABL1 gene exons and fusion gene breaking points. Exon 1 is alternatively 
spliced. Modified from De Braekeleer et al. 2011. 109 
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2.2.6 Tyrosine kinase inhibitors (TKIs) in the treatment of CML 
2.2.6.1 Treatment of CML before the TKI era  
 
The history of CML reveals many attempts to treat the disease with highly toxic and 
unselective agents. The earliest attempts were conducted with arsenic at the end of 
19th century; this treatment resulted in shrinkage of the spleen and improvement in the 
leukocyte count and anemia, but the response lasted only few months. 110 
Radiotherapy, mainly given to the spleen, was introduced at the beginning of 20th 
century. This therapy mode induced a rapid decrease in spleen size and leukocyte 
count, and the response lasted from weeks to months and occasionally years. 111 The 
third major therapy mode was busulfan, which came into the clinic in the 1950s and 
was the treatment of choice for the next 35 years. Busulfan was found to be more 
effective and convenient than radiotherapy, and increased the survival of CML 
patients. 112,113  
 
Busulfan was replaced by hydroxyurea and interferon-alpha (IFN-α), which 
manifested less toxic effects. Hydroxyurea was more effective than busulfan in terms 
of prolonging survival, 114 and turned out to be an excellent debulking agent by its 
effective normalizing of blood counts. It is commonly used as an adjuvant prior to 
more specific therapy modes. Due to a lack of cytogenetic responses, hydroxyurea 
never gained position as a first line therapy. 115 Usage of IFN-α began in the early 
1980s; it increased the survival of CML patients when compared to busulfan and 
hydoxyurea, and was most effective as a combination therapy with low-dose 
cytarabine. 116  
 
Allogeneic hematopoietic stem transplantation (HSCT) was tested experimentally as a 
treatment mode as early as 1979 117 and provided a cure for the disease. In the 1980s, 
it became more popular as the HLA-matching techniques developed. 118 In a follow-
up study conducted in 2005, the 15-year (patients collected 1982-92) overall survival 
rate was 53 % with allogeneic HSCT patients. 119 Allogeneic HSCT rates have 
declined since the introduction of TKI therapy for treatment of CML, but it is still an 
option for those patients in advanced phases and following treatment failure with 
TKIs. 120 
 
2.2.6.2 Imatinib 
  
The specific BCR-ABL1 inhibitor, imatinib mesylate, was initially known by the 
names GCP 57148 or STI571 121,122. The lead compound, a phenylaminopyrimidine 
derivative, was identified in an inhibitor screening study against PKC. Chemical 
modifications increased the cellular activity, TK specificity, solubility, and oral 
bioavaibility, while decreasing unwanted PKC activity. 122 Imatinib was an efficient 
inhibitor of ABL1 tyrosine kinases (BCR-ABL1 and the normal counterpart) 123 as 
well as other kinases, such as discoidin domain receptor 1 (DDR1), PDGFR-α/β, C-
KIT, ARG, and NGO2. 124  
 
The first indication for imatinib as a possible treatment for BCR-ABL1 positive 
leukemias was indicated in preclinical studies with p210 BCR-ABL1 expressing cell 
lines, whose ability to proliferate were inhibited with imatinib. Imatinib also induced 
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a 92-98% decrease in BCR-ABL1 positive colonies in colony-forming assays 
performed with primary blood and BM samples, whereas normal colony formation 
was unaffected. 123 An effective reduction of BCR-ABL1 phosphorylation and 
induction of apoptosis was visible in both BCR-ABL1 expressing cell lines and 
primary patient samples. 125 Imatinib also showed inhibitory activity with primary 
ALL samples, 125 ALL cell lines, 121,126 and TEL-ABL1 expressing cell lines. 121 The 
efficacy of imatinib was further confirmed in in vivo mice experiments in which dose-
dependent inhibition of tumor growth 123, blockage of BCR-ABL1 phosphorylation, 
and increased tumor-free survival were observed with imatinib therapy. 127 Imatinib 
also corrected splenomegaly and PB leukocyte counts in mice with CML-like disease 
induced by retroviral transduction of transplanted BM. Leukemic cells originated 
from these mice also had decreased levels of phosphorylation in the BCR-ABL1 
downstream molecules STAT5, CRKL, and SHC, following imatinib treatment. 128  
 
2.2.6.3 Mechanism of tyrosine kinase inhibition with imatinib 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Mechanism of inhibition of BCR-ABL1 function with imatinib. On the left, 
adenosine triphosphate (ATP) is bound to the active site of BCR-ABL1. BCR-ABL1 
catalyses the phosphorylation of a tyrosine residue on the substrate molecule, which 
leads to activation of the signaling pathways required for generation of CML. On the 
right, imatinib occupies the active site of BCR-ABL1, thereby preventing 
phosphorylation of tyrosine residues on the substrate. Modified from Savage et al. 
2002. 129 
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The mechanism of binding of imatinib to BCR-ABL1 was revealed with 
computational docking studies and X-ray crystallography. 122,130 Imatinib binds to the 
catalytically inactive form of the ABL KD and is therefore a type II inhibitor. In this 
inactive conformation, the activation loop is unphosphorylated and in a closed 
conformation and the conserved DFG motif in the N-terminal part of the loop is 
pointed outward. The active conformation of the activation loop would instead be 
open, enabling substrate binding. The inactive conformation provides specificity for 
imatinib, since this conformation differs from that of other kinases.  The nitrogen of 
the pyrinidyl ring in imatinib accepts a hydrogen bond from the amide of M318 of 
BCR-ABL1, a bond that is normally formed with N1 nitrogen in ATP. The side chain 
of T315 also forms a hydrogen bond with the secondary amino group in imatinib. 
T315 is replaced with methionine in many other kinases, rendering the possibility to 
form a hydrogen bond with imatinib. This so-called gatekeeper residue is therefore 
essential for the specificity of imatinib to BCR-ABL1. In total, imatinib forms six 
different hydrogen bonds and the majority of the binding is mediated by van der 
Waals interactions. 24,130 Binding of imatinib prevents autophosphorylation of BCR-
ABL1, thereby preventing phosphorylation of downstream signaling molecules 
essential for leukemogenesis, which eventually leads to inhibition of proliferation and 
apoptosis (Fig. 7). 123,125 
 
2.2.6.4 Clinical efficacy of imatinib therapy 
 
Despite the existence of other potential kinase targets, CML was chosen as an 
indication for the first clinical phase I studies conducted with imatinib. The reason for 
this was its well-characterized pathogenesis and the oncogene addiction caused by 
BCR-ABL1. Monitoring of clinical responses with leukocyte counts was also highly 
feasible compared to solid tumors. 122 Imatinib was rapidly shown to be superior to 
other therapy modes, and was chosen as a first line therapy mode for CML in 2001. A 
phase II clinical trial was conducted with 532 IFN-α -failure CML patients; imatinib 
was judged as a safe and efficient therapy mode for this type of patient group after a 
6-year follow-up. 131 The next phase 3 trial, the International Randomized Study of 
Interferon and ST1571 (IRIS) study, enrolled 1106 newly-diagnosed CML patients, 
who received either imatinib or IFN-α combined with cytarabine. Imatinib was shown 
to be superior to the IFN-α/cytarabine arm in terms of better tolerability, quality of 
life, and therapy response. Differences in therapy response were remarkable: the 
cytogenetic response rates at 18 months were 84% in the imatinib arm and 35% in the 
IFN-α/cytarabine arm. For this reason, the majority of patients in the IFN-
α/cytarabine were switched to the imatinib arm. 132-134 Long-term follow-up of these 
patients at 6 years has confirmed the efficacy of imatinib therapy, since the event-free 
survival was 83%, freedom from progression to advanced disease was 93% and 
overall survival was 88%. 135 
 
A proportion of patients fail to respond to imatinib, which can be either due to 
primary resistance characterized by the absence of an initial response, or to acquired 
resistance, where the patient loses the response. Resistance can be further divided into 
hematologic, cytogenetic, and molecular resistance based on clinical and laboratory 
criteria. 136 Initial response rates are lower in patients with advanced-stage disease and 
responses tend be short-lived in this patient group compared to the responses seen in 
chronic phase patients. 137,138 The main reason for imatinib resistance is the existence 
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of various point mutations; to date, 90 different point mutations have been 
documented. 136,139 These mutations are more frequently associated with acquired 
resistance compared to primary resistance and the likelihood for detection is increased 
in advanced stages of the disease. 140 
 
Imatinib-therapy shows also efficacy among Ph+ ALL patients, 141,142 but these 
patients tend to progress rapidly and develop resistance 142. Combining imatinib with 
chemotherapy has shown more promising results with Ph+ ALL patients preceding 
allogeneic HSCT. 143,144 Imatinib can be used in treatment of patients with 
gastrointestinal stromal tumors (GIST) who carry a mutated C-KIT, 145 
hypereosinophilic syndrome or chronic eosinophilic leukemia with FIP1L1-PDGFRα 
fusion kinase, 146 C-KIT –driven systemic mastocytosis, 147 and chronic 
myeloproliferative diseases with PDGFβ rearrangements. 148 The latest indication for 
imatinib therapy is dermatofibrosarcoma protuberans, a rare skin cancer with 
deregulated expression of PDGFβ. 149 
 
2.2.6.5 Second generation inhibitors nilotinib and dasatinib  
 
Dasatinib (formerly BMS-354825) has a broad kinase inhibition profile compared to 
imatinib, with main targets consisting of BCR-ABL1, ABL, C-KIT, PDGFR, and 
SRC family kinases (SRC, FGR, FYN, HCK, LCK, LYN, and YES) (Fig. 8). In total, 
dasatinib inhibits more than 30 different kinases. 124 The potency of dasatinib for 
unmutated BCR-ABL1 is over 300 times higher than that of imatinib and it was able 
to inhibit many mutated BCR-ABL1 isoforms that cause imatinib resistance. 150 
However, some point mutations are inaccessible by dasatinib: e.g., T315I/A, F317 
L/V/C, and V299L. 139,151 
 
The main indications for dasatinib therapy have been imatinib resistant CML and Ph+ 
ALL 152,153, but dasatinib has been approved also for the treatment of newly diagnosed 
CML patients. The SRC/ABL Tyrosine Kinase Inhibition Activity Research Trial C 
(START-C) evaluated the efficacy of dasatinib on CML patients who were intolerant 
of or resistant to imatinib. The response rates at 15 months were: complete 
hematologic response (CHR), 91%; major cytogenetic response (MCyR), 59%; and 
complete cytogenetic response (CCyR), 49%; with 96% overall survival. Therefore, 
dasatinib provided an efficient treatment mode for patients who were unresponsive to 
imatinib. 152 A phase 3 DASISION study compared dasatinib versus imatinib in newly 
diagnosed chronic-phase CML patients. 154 Recent results from a 2-year follow-up 
study showed faster and deeper responses in favor of dasatinib. 155 
 
Clinical trials have also shown efficacy of dasatinib in imatinib resistant and 
intolerant Ph+ ALL patients 156 and in newly diagnosed Ph+ ALL patients when 
steroids are combined as an induction therapy. 157 Assessment of dasatinib in the 
treatment of solid tumors such as breast cancer, prostate cancer, and melanoma is also 
ongoing in several clinical trials, as reviewed by Montero. 158 
 
Nilotinib (formerly AMN107) inhibits BCR-ABL1 with 20 times higher potency than 
imatinib and has the ability to inhibit imatinib-resistant mutations, except for T315I. 
159,160. Other nilotinib-resistant mutations seen in patients are E255K/V, Y253H, and 
F359V/C/I 139. The kinase inhibition spectrum is much narrower compared to 
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dasatinib (Fig. 8) and the main targets, in addition to BCR-ABL1, are C-KIT and 
PDGF receptors 124. Nilotinib is an effective treatment for CML with imatinib 
resistance and tolerance, 161-163 although in imatinib-resistant Ph+ ALL patients, 
nilotinib showed only limited efficacy. 161 Patients with nilotinib-resistant mutations 
had less favorable responses to nilotinib. 164 A phase 3 study, called Evaluating 
Nilotinib Efficacy and Safety in Clinical Trials–Newly Diagnoses Patients 
(ENESTnd), compared imatinib and nilotinib in newly diagnosed CML patients. As in 
the case of dasatinib, responses with nilotinib were faster and deeper when compared 
to imatinib responses. 165,166 Also nilotinib has been approved for the treatment of 
newly diagnosed CML patients. 
 
 
 
 
 
 
 
Figure 8. Comparison of the kinase inhibition spectrum and the affinity of nilotinib, 
imatinib, and dasatinib throughout the kinome. Kd (dissociation constant) describing 
the affinity of inhibitor to kinase. Reprinted with permission. © 2012 Elsevier. 167 
 
 
2.2.6.6 Other tyrosine kinase inhibitors that target BCR-ABL1 
 
Bosutinib (previously SKI-606) is a second-generation TKI with a target spectrum 
consisting of BCR-ABL1, SRC, TEC, and STE20 family kinases. In contrast to 
imatinib, dasatinib, and nilotinib, bosutinib does not inhibit C-KIT and PDGF 
receptors. However, as seen with other TKIs, the T315I and V299L mutations were 
inaccessible with bosutinib. 168,169 Bosutinib demonstrated efficacy with imatinib-
resistant and tolerant CML patients. 170 Patients who had failed either with dasatinib 
or nilotinib, or both, also benefited from bosutinib therapy. Bosutinib therapy induced 
responses with patients carrying dasatinib-resistant F317L mutation and nilotinib-
resistant F359C/I/V mutations. 171 Bosutinib was recently approved for the treatment 
of CML patients with tolerance to other therapies.  
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Bafetinib (INNO-406) is a BCR-ABL1 inhibitor with specific LYN (SRC family 
kinase) targeting properties, but this inhibitor has no efficacy against the T315I 
mutation 172. Clinical trials with imatinib resistant and intolerant CML and Ph+ ALL 
patients are ongoing. Bafetinib showed efficacy with patients resistant to multiple 
TKIs in a phase 1 study, although further studies are required to evaluate its efficacy. 
173 
 
Treatment options for patients with resistance to imatinib and second-generation TKIs 
are scarce. In the case of the T315I mutation and advanced phase CML, allogeneic 
stem cell transplantation is recommended. 174 IFN-α therapy has been effective in 
combination with imatinib and new studies evaluating IFN-α as combination with 
dasatinib and nilotinib are about to start. 175 In some rare cases, IFN-α has been able 
to induce responses in combination with TKIs in patients carrying the T315I 
mutation. 176,177  
 
Third generation TKIs are emerging in the field of CML therapy, to overcome the 
resistance seen with previous inhibitors. In their development, emphasis has been on 
the T315I mutation and several candidates are on preclinical and phase 1 trials. 174 
One of the most promising TKIs able to inhibit the T315I mutation is ponatinib 
(AP24534). In addition, Ponatinib inhibits SRC, VEGFR, FGFR, and PDGFR family 
kinases. 178 Clinical trials with ponatinib are ongoing and initial results from a phase 2 
trial, called The Ponatinib Ph+ ALL and CML Evaluation (PACE), involves CML 
and Ph+ ALL patients with dasatinib and/or nilotinib intolerance or resistance 
(including T315I). Results are promising: after a 6 month follow-up, 38/61 of chronic 
phase CML patients with the T315I mutation had entered major CyR.179  
 
2.2.6.7 Mechanisms of imatinib  resistance in CML 
  
Mechanisms behind imatinib resistance have been well defined. The major reason for 
resistance is BCR-ABL1 dependent, but mechanisms independent from BCR-ABL1 
have also been defined. In patients, the main reason for imatinib resistance are point 
mutations in the BCR-ABL1 genes, which result in amino acid changes in the drug-
binding site; over 90 different imatinib-resistant mutations have been defined in 
patients. 139 These mutations are present in different parts of the KD: the activation 
loop, the phosphate binding P-loop, and the hinge region. 180 The imatinib-resistant 
mutated clones probably pre-exist at minute levels before start of imatinib-therapy, 
but expand during the course of the treatment as result of selective pressure. 181 
Imatinib-resistant mutations, including T315I, have been observed previously before 
therapy administration and at the time of diagnosis 182,183  
 
A characteristic of imatinib-resistant mutations is a shift to a more active 
conformation, because of destabilization of the P-loop and the DFG motif. This 
conformational change increases the free energy needed for imatinib binding and 
mutations in the P-loop are responsible for this kind of destabilization of inactive 
conformation. The T315I mutation is called the gatekeeper mutation in the hinge 
region as it is responsible for disrupting a key H-bond with imatinib. The substitution 
of threonine with isoleucine causes steric hindrance and the loss of hydrogen bond 
affinity with imatinib. 184 Nilotinib, similar to imatinib, is specific for the inactive 
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conformation of the KD. The nilotinib mechanism is efficient at inhibiting the 
imatinib-resistant mutations, most likely due to high affinity BCR-ABL1, which shifts 
the equilibrium towards the inactive state. 184 Dasatinib is able to bind both inactive 
and active states of the protein, and thus the binding properties are less stringent than 
for imatinib and nilotinib. This enables binding to many imatinib-resistant mutations 
and is also the basis for specificity for the SRC family kinases, since the active 
conformation of BCR-ABL1 and the SRC family KDs share structural similarities. 185 
Ponatinib is specific for the inactive DFG-out conformation, but also possesses a 
unique ethinyl linker, which is able to skirt the effects of the bulky isoleucine in the 
T315I mutation. 186  
 
A second BCR-ABL1 dependent mechanism of resistance is amplification of the 
BCR-ABL1 fusion gene, which has been reported in imatinib-resistant cell lines. 187 
This phenomenon is rarely seen in patients, since BCR-ABL1 gene amplification was 
only detectable in 2 out of 32 imatinib-resistant CML patients analyzed with 
cytogenetics 140. On the other hand, amplification of BCR-ABL1 might play a role in 
the primitive CD34+ cells, since protein expression was higher in these cells in 
patients with blast crisis than in patients in the chronic phase. 188 
 
Several BCR-ABL1 independent mechanisms have been also proposed. Differences 
in pharmacokinetics of imatinib, mediated by cytochrome P450 protein levels, can 
affect the imatinib plasma levels, 189 which in turn is associated with therapy 
responses. 190 Intracellular uptake of imatinib is mediated by different influx and 
efflux mechanisms. Regulation of imatinib influx by the human organic cation 
transporter (hOCT1) has been proposed to have an impact on cellular imatinib levels. 
191 Imatinib is also a substrate for the efflux protein MDR1 (Multi drug resistance 
protein 1, also known as ABCB1), a transporter associated with multidrug resistance. 
192 MDR1 is overexpressed in blast phase CML patients and is implicated in imatinib 
resistance. 187 
 
One theory for resistance is stem cell persistence against imatinib therapy; these cells 
then serve as a reservoir for the malignancy. 193 Different mechanisms behind stem 
cell resistance have been postulated; for example, reduced imatinib exposure in the 
BM niche or altered drug intake and efflux. 194 Primitive imatinib-resistant cells also 
possess higher amounts of BCR-ABL1 transcripts and protein compared to mature 
cells. 195 CML stem cells are also insensitive to other TKIs, such as dasatinib, 
nilotinib, and bosutinib. 195-197 
 
SRC family kinases have been implicated in the pathogenesis of CML, 198,199 while 
some evidence claims a more important role for Ph+ ALL. 200 High expression of 
HCK and LYN has been reported to take part disease progression and imatinib-
resistance. 201-204 TKIs, like dasatinib, that are able to inhibit SRC family kinases have 
the possibility to overcome resistance caused by overactive SRC signaling. Bosutinib, 
in particular, which is a specific inhibitor of LYN, has been implicated in causing 
superior responses compared to imatinib through LYN inhibition.  
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2.2.7 Monitoring of therapy response in CML 
2.2.7.1 Genetic techniques 
 
Several genetic techniques are utilized in the process of diagnosing of CML, which 
are also useful for monitoring the therapy response and evaluating prognosis.  
 
Diagnosis and follow-up of CML is based on presence of the Ph chromosome and the 
BCR-ABL1 fusion gene. At diagnosis, a sample can be either PB or BM, but once 
patient has reached a hematologic response (HR), BM as source of sampling for 
cytogenetic analysis is recommended. At diagnosis, the presence of the Ph 
chromosome is often noticed in G-banding analysis of metaphasic cells. Karyotyping 
with G-banding is a conventional cytogenetic technique that is able to detect 
abnormalities in chromosomes, such as deletions, inversions, insertions, and 
translocations in dividing cells.205 206 
 
At diagnosis, other chromosomal abnormalities are detectable, which are associated 
with the accelerated phase. A closer cytogenetic analysis is performed using BCR-
ABL1 specific fluorescence in situ hybridization (FISH) with 5´BCR and a 3´ABL1 
fluorescent probe with different colors. The FISH technique is based on fluorescently 
labeled probe hybridization into metaphase chromosomes, interphase nuclei, or 
extended chromatin fibers. FISH can be performed with either metaphase or 
interphase cells. 207  
 
After the introduction of TKIs as a therapy for CML and a high level of complete 
cytogenetic responses, the demand has increased for higher sensitivity analysis than 
FISH. The real-time quantitative polymerase chain reaction (RQ-PCR) is by far the 
most sensitive and accurate method and it is especially useful in monitoring minimal 
residual disease (MRD) from deoxyribonucleic acid (DNA), complementary 
deoxyribonucleic acid (cDNA), or ribonucleic acid (RNA) samples. RQ-PCR is a 
quantitative PCR method based on specific forward and reverse primers and 
measurable fluorescent dye. The amount of PCR product is determined by the number 
of cycles required to reach a certain threshold level in a proportional standard sample. 
208 RQ-PCR is now routinely used to monitor responses to TKI therapy in CML 
patients from PB samples. 207 The level of BCR-ABL1 transcript is determined in 
relation to reference genes such as GUS, ABL1, or BCR. The control gene has been 
chosen to meet certain criteria: the expression level should be similar to BCR-ABL1 at 
diagnosis, the mRNA stability should be similar to BCR-ABL1, and the primers 
should not amplify genomic DNA sequences. 209 Different break variants, e13a2 
(b2a2) or e14a2 (b3a2), are determined individually for each patient at the time 
diagnosis and the same variant is used during the follow-up.  
 
In HR, the blood leukocyte and platelet counts are normalized and spleen reverts to 
normal size, but these are not informative regarding the numbers of leukemic cells. 
The cytogenetic response is determined by the number of cells carrying the Ph 
chromosome, determined by conventional cytogenetics, and undetectable Ph positive 
cells in BM constitute CCyR. Patients with CCyR may still carry up to 109 leukemic 
cells, which can be detected by RQ-PCR.  The major molecular response (MMR) is 
defined by ≥3-log reduction of the BCR-ABL1 transcript to the reference gene. The 
patient is regarded as being in complete molecular response (CMR) when no BCR-
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ABL1 transcripts are detectable. Different responses are listed in Table 2. 210 The 
present way of reporting results is being replaced by a new international scale (IS) 
standard, because of the unreliable results seen with the log-system. The IS system 
aims to provide a more harmonized method between diagnostic laboratories. A score 
of 100% in the IS system is given to the baseline level of BCR-ABL1 in newly 
diagnosed patients, and a score of 0.1% indicates MMR (Table 2). 209 However, even 
deeper responses can be measured currently, referred to as MR4.0 (≥4 -log reduction), 
MR4.5, and MR5.0, which are comparable with 0.01%, 0.0032%, and 0.001%, 
respectively, on the IS-scale. 211 
 
 
Table 2. Responses to TKI therapy defined by BCR-ABL1 ratio and leukemic cell 
numbera, and the IS standard. Modified from Vigil et al. 2011. 210  
 
 
 
 
 
 
 
 
 
 
2.2.7.2 FACS techniques 
 
Fluorescence-activated cell sorting (FACS) can be utilized in the analysis of 
heterogeneous cell populations. The technique is based on the light scattering 
properties of cells: when labeled with fluorescently tagged chemicals, cells emit 
fluorescent light when excited with lasers. By the use of different cell surface 
markers, analysis of various cell populations can be conducted.212 In addition to 
phenotypic analysis, FACS can be used in functional studies measuring cytokine 
production213, cytotoxicity214 and apoptosis215. With the growing availability of 
conjugated monoclonal antibodies, sophisticated instrumentation and improved 
software, an increased amount of parameters can be analyzed using FACS. Currently  
19-parameter analysis is possible, although this is not a reality in clinical settings.216 
 
FACS is an essential tool in the analysis of leukemic clones, especially in ALL and 
acute myeloid leukemia (AML). 217,218 The use of FACS analysis is not commonly 
used in CML diagnosis and MRD analysis, as monitoring TKI-response with PCR 
methods is highly sensitive. A leukemia-associated phenotype is also not present in 
CML. However, CML progression is usually associated with clonal evolution for 
which FACS analysis is useful in determining the characteristics of the disease.219 
 
CML can also be monitored though intracellular staining. The phosphorylation of the 
CRKL protein downstream of BCR-ABL1 has been shown to indicate the presence 
and activity of the oncogenic fusion protein, however this method has not yet been 
adapted to routine clinical use.220 FACS bead assay has been developed for the 
detection of leukemic fusion proteins from lysed leukemia samples. Assay specific for 
analyzing the BCR-ABL1 fusion protein from CML patient samples has a bead-bound 
Leukemic 
cells 
Response IS standard 
score (%) 
1012 - 100 
1010 CHR 10 
109 CCyR 1 
106 MMR 0.1 
 CMR Undetectable 
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catching antibody specific for the BCR-part and a fluorochrome-conjugated detection 
antibody against the ABL1 part. The method was validated using BCR-ABL1 positive 
cell lines from CML and ALL patient samples. The sensitivity of the assay was 
between 0.1%-1%, indicating higher sensitivity than FISH or karyotyping, but less 
than quantitative PCR. Results with patient samples were concordant to those 
conducted with PCR, although sensitivity of the assay may be problematic in the 
assessment of MRD. Benefits over traditional PCR and cytogenetic techniques are 
faster processing time and freedom from specialized laboratory facilities. Specific 
analyses of the different BCR-ABL1 variants are not needed, since the assay is 
specific for all of them. Fusion protein analysis can also be combined simultaneously 
with other FACS analyses. Due to these benefits FACS analysis of BCR-ABL1 
protein has recently entered routine clinical use.221 
 
2.2.8 Prognostic factors for therapy outcomes in CML 
2.2.8.1 Factors based on clinical features 
 
Prognostic scoring systems predicting therapy responses have existed since before the 
imatinib era. One widely used system is the Sokal score, derived from CML patients 
using mainly busulfan. This factor is based on diagnostic phase age, spleen size, 
platelet count, and PB blasts and it separates patients into low, intermediate, and high-
risk groups by predicting 4-year survival probabilities. 222 The Sokal score was 
insufficient at discriminating between low and intermediate risk groups in IFN-α-
treated patients. Therefore, a new prognostic factor was derived, the Hasford score, 
which also includes blood eosinophils and basophils in the variables. 223 Deletions at 
the 9;22 breakpoint, 224 and a lack of certain regions in the chromosome 9, also 
implicated poor prognosis for patients treated with IFN-α and hydroxyurea. 225 After 
introduction of imatinib as the treatment for CML, the efficacy of these parameters 
has shown less potential. For example, deletions in chromosome 9 no longer influence 
the survival of imatinib-treated patients 226 or patients treated with second generation 
TKIs. 227 The IRIS study concluded that Sokal scores given to patients at their 
diagnostic phases correlated with their rates of cytogenetic responses with imatinib 
treatment, with the lowest rate occurring in the high-risk group. The risk for disease 
progression was also significantly higher for the high-risk group. 228 However, the 
Sokal score did not correlate with disease progression after achieving a CCyR among 
imatinib-treated patients 228, while the Sokal score was an important predictor of 
outcome after achieving CCyR with IFN-α -treated patients. 229 European 
LeukemiaNet has developed new scoring system EUTOS (European Treatment and 
Outcome Study) on the basis of newly diagnosed CML patients treated with imatinib-
based regimens. This factor is based on the percentage of basophils and spleen size 
and divides patients into low and high-risk groups. Validation of the EUTOS score 
stated that 34% of CML patients failed to achieve CCyR in 18 months in the high-risk 
group. 230 The effectiveness of EUTOS score was questioned in a recent study, as it 
was unable to predict outcome of CML patients treated with imatinib or second 
generation TKIs. 231 
 
The response time is also connected to the imatinib therapy outcome133,228. The 
achievement of MMR within a 12-month time frame is associated with a longer 
duration of CCyR in imatinib-treated patients and considered a predictive factor for a 
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good clinical outcome. 232 Failure to achieve MMR within 12 months is associated as 
a risk factor, while failure within 18 months is considered a suboptimal response.233 
Similar predictive values (MMR, MCyR) have also been demonstrated with second-
generation TKIs after imatinib-failure. 234,235 A recent publication demonstrates that 
the measurement of BCR-ABL1 transcripts in accordance to the IS scale can predict a 
clinical outcome for TKIs in as early as 3 months also. 236,237 
 
2.2.8.2 Predictive genetic factors 
 
As the traditional parameters have somewhat limited efficiency, a demand has grown 
for new prognostic factors such as biomarkers. Genetic approaches have discovered 
differentially expressed genes in cells from primary patient with different disease 
stages. 238,239 Multiple studies have identified a set of differentially expressed genes 
according to the imatinib response. 240-244 However, the results have not clearly 
indicated the genes connected to the imatinib response and one of these studies was 
unable to predict a cytogenetic response to imatinib. 245   
 
Different kinds of genetic polymorphisms have also been identified in association 
with the imatinib response. These genes are usually associated with drug absorption, 
distribution, metabolism, and excretion. This is likely connected to the fact that higher 
imatinib plasma levels are associated with better responses 190. Different 
polymorphisms, such as T1236C, G2677T/A, and C3435T, in the ABCB1 gene that 
encodes the MDR1 efflux protein are associated with certain imatinib responses. 246 
The same kind of association has been discovered for the polymorphic variants 
C421A and G34A of the ABCG2 gene that encodes another imatinib efflux protein, 
the breast cancer resistance protein (BCRP). 247 Low hOCT1 protein activity is 
associated with lower probability of MMR, 248 and consequently high expression of 
this imatinib influx protein is connected with better survival and responses, while a 
similar connection with the previously mentioned efflux proteins was absent. 249 The 
C480G and A1222G polymorphisms in the hOCT1-encoding SLC22A1 gene also 
show some predictive characteristics. 247,250 Finally, the CYP3A5 gene responsible 
encoding of the imatinib-metabolizing enzyme, P450, predicts a response for imatinib 
through polymorphism at A6986G. 250 In general, the results from different studies 
are conflicting, depending on the ethnicity of the patients, group size, drug dosage, 
and study design, as concluded in a review article by Dulucq and Krajinovic. 251 
These findings diminish the usability of these genetic polymorphisms as biomarkers 
for the imatinib  response. 
 
Germ line polymorphism in the BIM gene encoding for BCL2-like (BIM) protein has 
been linked to imatinib. Deletion in intron 2 was noticed to favor splicing of exon 3 
over exon 4 of the BIM gene. Expression of exon 3 resulted in expression of a BIM 
isoform that lacked the pro-apoptotic BCL2-homology domain (BH3) that causes 
imatinib resistance in CML and EGFR-mutated NSCLC cell lines. Resistance to 
imatinib was overcome with BH3 mimetic drugs. This polymorphism in the BIM gene 
was also more common in East Asian population (12.3 %), while absent in European 
and African individuals. The BIM deletion polymorphism was associated with clinical 
resistance in CML patients treated imatinib, since patients with the polymorphism 
causing this deletion had poorer responses to imatinib compared to patients without 
the polymorphism. 252 In East Asia, the frequency (∼50%) of incomplete cytogenetic 
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responses is higher among imatinib-treated CML patients 253 when compared to 
European and North American patients (26 %), 134 which can be partly explained by a 
different genetic background. Authors estimate that BIM polymorphism might be 
responsible for 21% of the imatinib resistance seen in East Asia and suggest it as a 
germline biomarker for TKI resistance, as it is easily testable during diagnosis. 252 
 
In addition, CML patients with a killer immunoglobulin-like receptor (KIR) 2DS1 
genotype predicted a failure to achieve CCyR and inferior progression free survival 
and overall survival. 254 A specific IFN-γ genotype was also connected with CCyR 
and MMR in Canadian and Korean patients, suggesting a role for IFN-γ signaling in 
CML pathogenesis. 255  
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3 AIMS OF THE STUDY 
 
The overall aim of the study was to characterize aberrant cell signaling patterns in 
CML cells and in normal leukocytes during TKI therapy and to discover novel 
biomarkers for therapy response. In addition, we aimed to understand the molecular 
basis of TKI response in a Ph negative ALL patient. 
 
Specific aims of the subprojects included: 
 
1) To investigate the molecular mechanism underlying ABL1-driven ALL 
 
2) To characterize the effects of TKI therapy on immune cell function in CML and 
associate the signaling pattern with therapy responses 
 
3) To develop a novel automated method for FACS data analysis 
 
4) To discover novel biomarkers for the imatinib response in CML patients 
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4 PATIENTS AND METHODS 
 
4.1 Patients and ethical permissions 
 
The patient in Study I (patient #1, Table 3) had a pre-B ALL. The patient had a 
treatment history of dasatinib combined with chemotherapy, prior to allogeneic 
HSCT. The patient relapsed after the transplantation and continued with dasatinib 
therapy. Sample for Study I was obtained during the diagnosis. 
 
Study II consisted of 10 CML patients in the diagnostic phase and 10 imatinib-treated 
and 10 dasatinib-treated CML patients (Table 3), all in chronic phase. Most of the 
patients had a CCyR, while one imatinib-treated patient (patient #3) had partial 
cytogenetic response with 25 % Ph + cells in the BM; one dasatinib-treated patient 
was only in HR (patient #18). Most of the dasatinib-treated patients had been treated 
with imatinib prior to dasatinib therapy due to inadequate responses (excluding 
patients #8 and #11). Four patients (patients #16, #19, #21, and #24) had also been 
treated with IFN-α before imatinib. The same patient data were used in Study III. 
 
Study IV included 10 diagnostic phase CML patients, who achieved either MMR or 
CMR for imatinib at 18 months. These patients were designated as an optimal 
response group. The suboptimal response group, with 10 diagnostic phase patients, 
achieved CCyR, but no MMR after 18 months of imatinib therapy. Patients #27, #28, 
#30, and #31 also received IFN-α after 3 months imatinib monotherapy. The standard 
400 mg dose was increased to 600-800 mg after 3-12 months of therapy due to 
suboptimal response with 5 patients (#13, #33, #35, #36, and #37). This study also 
included patients who had failed with TKI therapy. One chronic phase CML patient 
(#39) achieved only HR for imatinib and carried an imatinib-resistant M351T 
mutation. This patient did not achieve a cytogenetic response to either bosutinib or 
nilotinib. Chronic phase patient #40 achieved a minimal cytogenetic response 
(MinCyR) for imatinib and nilotinib and patient #41 was in blast crisis during BM 
sampling after a short period of imatinib therapy. 
 
Study II included 7 healthy controls for blood samples and Study IV included 4 
healthy controls for BM samples; these persons had median ages of 25 and 29 years, 
respectively, and normal blood counts. 
 
The study was conducted in accordance with the principles of the Declaration of 
Helsinki and was approved by the Helsinki University Central Hospital Ethics 
Committee. Written informed consent was obtained from all patients and healthy 
controls. 
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Table 3. Patient characteristics  
 
 
 
 * dasatinib in combination with chemotherapy, ** therapy history with imatinib, 
bosutinib and dasatinib, *** therapy history with imatinib and nilotinib, BC=blast 
crisis; LR, low risk; IR, intermediate risk; HR; high risk. 
 
 
 
 
 
 
Pt # Malignancy Age Gender Treatment  
Dosage/ 
mg 
Sokal 
group 
(CML) 
Response at 
sampling/mo 
(study II) 
Imatinib 
treatment 
response 
18 mo 
(study 
IV) 
Study 
 
 
1 B-ALL 40 Male Dasatinib* 140 n/a n/a n/a I 
2 CML 43 Male Dg/Imatinib 400 LR CCyR/6 n/a II,III 
3 CML 73 Male Dg/Imatinib 400 HR PCyR/5 n/a II,III 
4 CML 49 Male Dg n/a LR n/a n/a II,III 
5 CML 63 Female Dg/Imatinib 400 IR n/a CMR II,III,IV 
6 CML 34 Female Dg/Imatinib 400 LR CCyR/5 CMR II,III,IV 
7 CML 30 Male Dg/Imatinib 400 LR n/a MMR II,III,IV 
8 CML 45 Male Dg/Dasatinib 100 LR CCyR/6 n/a II,III 
9 CML 55 Female Imatinib 400 IR CCyR/21 n/a II,III 
10 CML 62 Male Dg/Imatinib 400 LR n/a MMR II,III,IV 
11 CML 60 Female Dg/Dasatinib 100 IR CCyR/6 n/a II,III 
12 CML 55 Female Dg/Imatinib 400 IR CCyR/6 n/a II,III 
13 CML 41 Male Imatinib 400 IR CCyR/31 CCyR II,III,IV 
14 CML 61 Male Imatinib 400 LR CCyR/21 CCyR II,III,IV 
15 CML 53 Male Imatinib 400 IR CCyR/19 CCyR II,III,IV 
16 CML 57 Male Imatinib 400 IR CCyR/31 n/a II,III 
17 CML 60 Male Imatinib 400 LR CCyR/26 n/a II,III 
18 CML 73 Male Dasatinib 100 HR CHR/1 n/a II,III 
19 CML 30 Male Dasatinib 100 LR CCyR/16 n/a II,III 
20 CML 65 Female Dasatinib 100 IR CCyR/16 n/a II,III 
21 CML 53 Male Dasatinib 140 LR CCyR/37 n/a II,III 
22 CML 28 Female Dasatinib 140 HR CCyR/37 n/a II,III 
23 CML 64 Male Dasatinib 100 HR CCyR/20 n/a II,III 
24 CML 42 Male Dasatinib 100 HR CCyR/35 n/a II,III 
25 CML 68 Male Dasatinib 100 LR CCyR/3 n/a II,III 
26 CML 49 Male Imatinib 400 LR n/a CMR IV 
27 CML 48 Male Imatinib 400 IR n/a CMR IV 
28 CML 38 Female Imatinib 400 LR n/a CMR IV 
29 CML 51 Female Imatinib 400 LR n/a CMR IV 
30 CML 55 Male Imatinib 400 LR n/a CMR IV 
31 CML 72 Male Imatinib 400 IR n/a CMR IV 
32 CML 43 Male Imatinib 400 LR n/a CCyR IV 
33 CML 35 Male Imatinib 400 LR n/a CCyR IV 
34 CML 67 Male Imatinib 400 LR n/a CCyR IV 
35 CML 27 Male Imatinib 400 LR n/a CCyR IV 
36 CML 54 Male Imatinib 400 IR n/a CCyR IV 
37 CML 62 Female Imatinib 400 IR n/a CCyR IV 
38 CML 40 Male Imatinib 400 IR n/a CCyR IV 
39 CML 51 Female ** n/a HR n/a CHR IV 
40 CML 69 Male *** n/a HR n/a MinCyR IV 
41 CML 35 Male Imatinib n/a  HR n/a BC IV 
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4.2 Methods 
4.2.1 Mononuclear cell isolation from blood and bone marrow (BM) and 
storage (I, IV) 
 
Mononuclear cells were isolated from blood (Study I) and BM (Study IV) with the 
Ficoll-Paque system (GE Healthcare, Piscataway, NJ, USA), according to the 
manufacturer´s instructions. Cells were washed once with phosphate buffered saline 
(PBS) and counted before snap freezing as pellets at -70 oC. Portions of the BM 
samples were cryopreserved in fetal bovine serum (FBS, Lonza, Basel, Switzerland) 
and 10 % dimethyl sulfoxide (DMSO). 
4.2.2 Cell culture (IV) 
 
K562 cells (Sigma Aldrich, St. Louis, MO, US) and EM-2 and MOLM-1 cell lines 
(both DSMZ, Braunschweig, Germany) were grown in RPMI 1640 media containing 
10% FBS (20% for MOLM-1), 2mM L-glutamine, 1% penicillin and 1% 
streptomycin (all Lonza). Cells were washed once with PBS before freezing at -70 oC 
as snap-frozen pellets. 
4.2.3 Cytogenetic characterization of the t(1;9)(q24;q34) translocation (I) 
 
Patient #1 was analyzed with a routine G-banding method during diagnosis. More 
detailed analysis was performed with multicolor FISH (Metasystems GmbH, 
Altlussheim, Germany), chromosome 9 painting and FISH primers designed to bind 
1p36 and 1q25 regions of chromosome 1. The patient was also analyzed using a BCR-
ABL1 fusion gene with a BCR-ABL1 ES dual color extra signal translocation probe 
(Vysis®, Abbott Laboratories, IL, USA) and PCR analysis. 
  
4.2.4 PCR reaction and DNA sequencing of the RCSD1-ABL1 fusion gene (I) 
 
RNA and cDNA were generated by standard molecular biology methods from a pre-B 
lymphoblastic leukemia patient’s sample (patient #1). Forward PCR primers were 
designed to anneal with the RCSD1 gene and reverse primers with the ABL1 gene 
(Table 4, Fig. 9). Reverse primers were designed to overlap with the ABL1 KD, 
which is situated in the exons 5-7 of the ABL1 gene. The PCR reactions were 
performed with all six possible primer combinations with 0.5 µM concentrations 
each.  Other reagents of the PCR reaction included: Phusion polymerase (1U), GC 
buffer (1x), dNTP mix (200 µM) (all Finnzymes, Espoo, Finland) and 125 ng  
template DNA (patient cDNA or control cDNA) or water as a control. The PCR 
program consisted of initial denaturation (30s/98oC), 30 cycles of denaturation 
(10s/98 oC), + annealing (30s/62 oC), + extension (10min/72 oC), and a final extension 
(10min/72 oC).  
 
PCR products were analyzed with 1% and 2% agarose gels with a 1 kb DNA ladder 
(New England Biolabs, Ipswich, MA, USA). PCR products were purified with a 
QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany) from the 2 % agarose gel 
and sequenced with their respective primers.  
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Table 4. Primers designed for analysis of the RCSD1-ABL1 fusion gene. 
 
Primer Sequence Gene Exon 
RCSD1-aF 5’-CCTGAAGGACATGGAGGAAA-3’ RCSD1 1-2 
RCSD1-bF 5’-CAGAGACCAATGCCAATGTG-3’ RCSD1 2 
ABL1-aR 5’-CTGCACCAGGTTAGGGTGTT-3’ ABL1 6 
ABL1-bR 5’-TGGTGTCCTCCTTCAAGGTC-3’ ABL1 5-6 
ABL1-cR 5’- TCTGAGTGGCCATGTACAGC-3` ABL1 7 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. RCSD1-ABL1 fusion gene and annealing sites of PCR primers. 
 
4.2.5 Single cell phosphoprotein analysis (II) 
 
Principle of single cell phosphoprotein analysis was to measure cytokine-induced 
phosphoprotein signals in individual leukocyte subtypes. The signaling proteins 
measured with this method were extracellular-signal-regulated kinase 1/2  (ERK1/2) 
and proteins belonging to the signal transducer and activator of transcription (STAT) 
family. 
 
ERK1/2 belongs to the MAPK family. ERK1/2 is involved in many cellular processes 
and is inducible with various mitogens, growth factors, and cytokines.  256 Activation 
STAT proteins are mediated with wide array of cytokines and growth factors. Binding 
of the extracellular ligand to its specific receptor results phosphorylation of Janus 
kinase protein (JAK) via the cytoplasmic part of the receptor. Activated of JAKs 
phosphorylate STAT proteins, which dimerize and enter the nucleus, where they take 
action as transcription factors. The JAK-STAT pathway is essential in mediating cell 
proliferation, differentiation, cell migration and apoptosis, but is also associated with 
different types of cancer. 257 
 
4.2.5.1 Ex vivo cytokine cell activation 
 
Freshly drawn blood in heparin tubes from healthy controls, diagnostic CML patients, 
and CML patients receiving imatinib and dasatinib (Table 3) were stored at +37 oC 
for a maximum of 1 hour before cytokine activation. Aliquoted samples were 
activated (15 min, +37 oC) with GM-CSF (100 ng/ml), a mixture of IL-2 (100 ng/ml), 
IL-10 (100 ng/ml), and IFN-α; 100 U/ml) and a mixture of IL-4 (100 ng/mL), IL-6 
(100 ng/ml), and IFN-γ (100 ng/ml). The manufacturer of IFN-α was PBL Interferon 
Source (Piscataway, NJ, USA) and GM-CSF, IFN-γ, IL-2, IL-4, IL-6, and IL-10 were 
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obtained from R&D Systems (Minneapolis, MN, USA). PBS stimulated blood was 
used as stimulation control and aliquots of blood without PBS or cytokine stimulation 
were used to determine baseline phosphoprotein analysis. Red blood cells were lysed 
with (10 min, RT) FACS lysing solution (BD Biosciences, San Jose, CA, USA) and 
samples were fixed with paraformaldehyde in PBS, with final concentration of 2 %. 
Cells were washed once with PBS to remove residual lysed red blood cells and stored 
in -70 oC). 
 
4.2.5.2 Phosphoprotein staining 
 
Antibodies used for the phosphoprotein flow cytometry were CD45 APC-H7, CD4 
PerCP, CD3 PE-Cy7, CD25 PE-Cy7, STAT3 A647 (Y705), STAT5a-A488 (Y694), 
STAT6 PE (Y641), ERK1/2 A488 (T202/Y204), STAT1 PE (Y701), and STAT1 
A488 (Y701) (BD Biosciences) (Table 5). Suitability of detecting the surface markers 
with the permeabilization step was first tested and optimal antibody concentrations 
were determined. Samples at -70 oC were thawed and washed with PBS. Cells were 
stained with CD45 APC-H7 (RT, 15 min), washed once with PBS, and permeabilized 
for 10 min on ice with -20 oC methanol. After removing the residual methanol with 
two PBS washes, the cells were stained with the remaining antibodies according to 
the individual antibody panel. Panels used in the staining were PBS-stimulated cells: 
panels 1−4; GM-CSF –stimulated cells: panels 1−2; IL-2, IL-10, IFN-α -stimulated 
cells: panels 1 and 3; of IL-4, IL-6, IFN-γ -stimulated cells: panels 1 and 4. After one 
hour of incubation on ice, the cells were washed and analyzed with a six-color flow 
cytometer (FACS CantoI or CantoII, BD Biosciences). 
 
 
Table 5. Antibody panels used in multicolor FACS analysis 
 
 
 
 
 
 
 
 
 
 
 
 
Panel  
A488 
 
PE 
 
PerCP 
 
PECy7 
 
A647 
 
APC-H7 
 A488 PE PerCP PE-Cy7 A647 APC-H7 
1 ERK1/2 STAT1 CD4 CD3 STAT3 CD45 
2 STAT5 STAT1 CD4 CD3 STAT3 CD45 
3 STAT5 STAT1 CD4 CD25 STAT3 CD45 
4 STAT1 STAT6 CD4 CD25 STAT3 CD45 
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4.2.5.3 Phosphoprotein data analysis 
 
Cell gating was performed with open access Cytobank software 
(http://www.cytobank.org/) and FACS Diva software (Version 6.1.2; BD 
Biosciences). Granulocyte, lymphocyte, and monocyte populations were gated from 
side scatter (SSC) versus CD45. Lymphocytes from this scatter were further gated 
according to CD4 expression, and regulatory T cells (Treg) were analyzed from CD4- 
and CD25 positive cells. Intracellular protein intensities STAT1, STAT3, STAT5, 
STAT6 and ERK1/2 were measured by subtracting the PBS-activated signal from the 
cytokine-activated signal. Baseline phosphoproteins were analyzed from samples 
without any activation (PBS or cytokine). Data were analyzed by comparing the 
different study groups with GraphPad (Version 5.2) software using the Kruskal-
Wallis test and Dunn’s Multiple Comparison test. The limit for a statistically 
significant result was set as p<0.05. 
 
4.2.6 IL-2, IL-4, IL-6, IL-10, IFN-α, IFN-γ, and GM-CSF concentration 
measurements (II) 
 
Plasma samples from healthy controls, diagnostic CML patients, and patients treated 
with imatinib and dasatinib were analyzed with a Human Cytokine 25-plex Panel 
(Invitrogen, Camarillo, CA, USA) according to the manufacturer’s instructions. 
Measurement and analysis were performed using a Bio-Plex 200 System (BioRad, 
Hercules, CA, USA). The measurement was conducted for corresponding time points 
as the cytokine activations were performed. 
  
4.2.7 Automated FACS data analysis (III) 
 
The FlowAnd FACS data analysis tools were implemented into the freely available 
Anduril framework developed by Ovaska et al. 258. Five different modules were built 
into the FlowAnd, including: data import, preprocessing, gating, population 
identification, and data analysis. The majority of these modules had been developed 
as part of previously developed software. The data import part was from flowCore 259 
and the gating module utilized three different clustering methods: SamSPECTRAL 
260, flowMEANS 261, and the mixture modeling from FLAME software 262. The 
clustering is associated with a graphical module, where the user can identify the 
clusters. FACS data from project II were utilized in this project to validate the 
reproducibility and feasibility of FlowAnd compared to manual analysis.  
  
4.2.8 Kinase target activation profiling (IV) 
4.2.8.1 Lysate preparation and kinase array 
 
The Proteome Profiler Human Phospho-Kinase Array Kit (R&D systems, 
Minneapolis, MN, USA) was used to analyze phosphorylation of 46 different kinase 
target sites (http://www.rndsystems.com/product_results.aspx?k=ary003). Diagnostic 
phase CML patient’s BM mononuclear cells (MNCs), with optimal and suboptimal 
imatinib responses, healthy control BM MNCs, K562, EM-2 and MOLM-1 cells were 
stored snap-frozen and thawed before analysis. Three additional patients, without 
	   42	  
appropriate therapy response to various TKIs, were also analyzed (Patients #39, #40 
and #41, Table 3). Cells were lysed according to the manufacturer’s directions (with 
lysis buffer from the Kinase Array Kit). In addition, Mini EDTA-free protease 
inhibitors (Roche Diagnostic, Mannheim, Germany) were used in the lysis buffer as a 
7x concentrate in PBS. Protein concentration was measured with a Qubit Fluorometer 
(Invitrogen, Carlsbad, CA, USA) and 300 µg protein was used in each experiment. 
Signal detection for the array was performed with Super Signal West Femto 
Maximum Sensitivity ECL reagents (Thermo Scientific, IL, USA). The x-ray films 
were exposed to the array membranes for several different exposure times. 
  
4.2.8.2 Data analysis 
 
X-ray images were scanned and intensities of each spot were analyzed by custom 
code in the Anduril analysis software 258. Spot intensities were analyzed by 
subtracting the background intensity obtained from negative PBS controls and the 
mean value was determined between duplicates. Optimal and suboptimal groups were 
compared with a non-parametric Mann Whitney test. Other statistical comparisons 
performed were healthy controls vs. CML patients and CML patients divided into low 
risk and intermediate Sokal risk factor groups.  
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5 RESULTS 
5.1 1;9 translocation (I) 
 
In order to understand the molecular mechanism of dasatinib sensitivity in an Ph neg 
ALL patient (patient #1), the diagnostic phase leukemic cells with cytogenetic and 
molecular methods was investigated. 
5.1.1 Clinical characterization of the patient 
 
The patient had been diagnosed with CD19+, CD22+, CD10+, cCD79a+, nTdT+, 
CD34+, CD38+, and HLA-DR+ B-ALL in March 2007 and BM aspirate showed 
80% of blast cells. The patient received two courses of cyclophosphamide, 
vincristine, doxorubicin (Adriamycin®) and dexamethasone (CVAD) as an induction 
therapy, but leukemia was chemotherapy resistant. FISH analysis after the 2 courses 
of CVAD revealed that still 50 % of blasts were in the BM. Based on the diagnostic 
phase cytogenetic results showing t(1;9) translocation, dasatinib (140mg once a day) 
therapy was initiated and after two-weeks the patient was in morphological remission 
and FISH analysis showed minimal residual disease with 1,5 % blast count. Dasatinib 
treatment was continued as consolidation therapy with methotrexate for four weeks, 
which resulted in CCyR. Dasatinib treatment was continued and HSCT was 
performed four months after diagnosis (July 2007). After HSCT no TKI therapy was 
used. Patient relapsed 1 year after the transplantation showing first cytogenetic 
relapse and a month later hematological relapse (August 2008). Patient started 
dasatinib therapy (70mg twice a day) with one cycle of high-dose chemotherapy and 
received CCyR. Since then dasatinib was continued as monotherapy and no 
additional cytotoxic drugs or donor lymphocyte infusions were given. 
 
5.1.2 Cytogenetic characterization of the t(1;9)(q24;q34) translocation  
 
G-banding and multicolor FISH analysis of the patient (Table 3) revealed a reciprocal 
translocation between chromosomes 1 and 9 (46,XY,t(1;9)(q24;q34) [5]/46, XY [3]), 
during diagnosis in 60% of the BM cells (Fig.10). Other translocations such as t(9;22) 
were undetectable. More specific analysis with probes specific for the 1p36 and 1q25 
regions of chromosome 9 confirmed the translocation. The BCR-ABL1 specific probe 
showed two green signals representing a normal BCR gene and three ABL1 signals. 
This indicated translocation between ABL1 from chromosome 9 and an unknown gene 
situated in chromosome 1 in a region centromeric to 1q25. 
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Figure 10. Cytogenetic characterization of BM of a pre-B acute lymphoblastic 
leukemia patient (Patient #1, Table 3) with G-banding. Chromosome 1 is circled in 
red and chromosome 9 in green. 
 
5.1.3 PCR reaction and DNA sequencing of the RCSD1-ABL1 fusion gene  
 
As the ABL gene was involved in the 1;9 translocation, and the patient showed a 
response to dasatinib, ABL-driven leukemogenesis was suspected. According to a 
publication by De Braekeleer 263, who describes a t(1;9)(q24;q34) translocation gene 
in an ALL patient, with a possible involvement of RCSD1 gene, a similar case was 
suspected in the present study. The molecular mechanism was examined in more 
detail and the possibility of RCSD1-ABL1 fusion was explored by designing a specific 
forward PCR primer for RCSD1 and a reverse primer for ABL1. The PCR reaction 
from patient #1, using diagnostic-phase cDNA, produced bands with sizes of 
approximately 500 bp (Fig. 11). Most of the bands included another neighboring band 
with similar size. PCR with negative and water controls did not yield any PCR 
products. The larger PCR product consisted of three first exons of RCSD1 gene (Fig. 
12) and in the smaller product the two first exons were included. In both of the cases 
RCSD1 was fused to the exon 4 of the ABL1 gene. 
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Figure 11. Agarose gel of PCR reactions generated with forward RCSD1 and reverse 
ABL1 primers. Lanes 1 and 14: NEB 1 Kb DNA ladder; lanes 2, 5, 8, 10, and 12: 
PCR products with patient #1 cDNA; lanes 3 and 6: negative control cDNA; lanes 4, 
7,9, 11, and 13: water control. aF, bF, aR, bR, and cR refer to primers listed in Table 
4. 
 
 
 
Figure 12. The RCSD1-ABL1 fusion gene formed between RCSD1 exon 3 and ABL1 
exon 4 (sequenced from a larger PCR product). 
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5.2 Single cell phosphoprotein analysis (II) 
 
The single cell phosphoprotein analysis method was chosen to study the immune cell 
function in CML patients at the diagnosis and during TKI therapy. This method is 
based on flow cytometry, which is able to measure phosphorylation levels of 
intracellular signaling proteins in distinct cell populations. Ex vivo cytokine 
stimulation was used to induce intracellular signaling activity. 
 
 
5.2.1 Feasibility of single cell phosphoprotein analysis 
 
The single cell phosphoprotein analysis method was optimized with healthy controls. 
The cell surface markers were able to discriminate monocytes, lymphocytes, and 
granulocytes from SSC vs. CD45 scatter and lymphocytes were further analyzed in 
the CD25 vs. CD4 scatter. The feasibility of the method was seen in the ability of the 
stimulating cytokines to induce cell specific intracellular signals. For example, GM-
CSF was able to induce ERK1/2, STAT1, STAT3, and STAT5a phosphorylation in 
myeloid cells, but not in lymphocytes. A combination of cytokines IL-2, IL-10, and 
IFN-α was able induce phosphorylation of STAT5a, STAT3, and STAT1, while IL-4, 
IL-6, and INF-γ stimulated phosphorylation of STAT6, STAT3, and STAT1. The 
induced signals were most prominent in monocytes and less active in lymphocytes 
and granulocytes. 
 
5.2.2 Basal phosphoprotein levels in CML patients 
 
Although CML patients in the diagnostic phase have monocytes and granulocytes that 
are mostly Ph+ cells, the unstimulated basal phosphoprotein levels were similar to 
those of healthy controls (Fig. 13). This was also the case with STAT5a, although 
STAT5 signaling is known to be activated in Ph+ positive CML cell lines 264. Basal 
phosphoprotein levels in Ph negative lymphocytes were also at the same level in both 
healthy controls and diagnostic CML patients (data not shown). 
 
Patient samples studied during TKI therapy contained Ph negative cells since most of 
the patients had achieved CCyR at the time of sampling. STAT3 phosphorylation was 
decreased significantly in monocytes and granulocytes of dasatinib-treated patients 
(Fig. 13), as well as in lymphocyte subpopulations (data not shown). None of the 
other phosphoproteins levels studied differed significantly from those of healthy 
controls (myeloid cells, Fig.13, lymphocytes data not shown). 
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Figure 13. Baseline phosphoprotein levels in myeloid cells (monocytes and 
granulocytes) of healthy controls, and in CML patients at the time of diagnosis (DG), 
during imatinib (IM) therapy, and during dasatinib (DAS) therapy. *p<0.05 
 
5.2.3 Responsiveness of diagnostic and TKI-treated CML patients for ex vivo 
cytokine activation 
 
GM-CSF induced strong signals through pERK1/2, pSTAT1, pSTAT3, and pSTAT5a 
in monocytes of healthy controls (Fig. 14). In monocytes of diagnostic-phase CML 
patients, the GM-CSF-induced signals were significantly lower in pERK1/2 (p<0.01), 
pSTAT1 (p<0.05) and STAT5a (p<0.05) (Fig. 14 A-C). The same trend was seen for 
the GM-CSF/pSTAT3 signal in monocytes (Fig. 14 D) and GM-CSF-induced signals 
in granulocytes, but the differences from healthy controls were not statistically 
significant (data not shown). However, the respective responses during imatinib and 
dasatinib therapy were corrected towards normal levels (Fig. 14) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Intracellular pERK1/2, pSTAT1, pSTAT5a, and pSTAT3 responses to GM-
CSF stimulation in monocytes of healthy controls, and in CML patients at diagnosis 
(DG) and during imatinib (IM) and dasatinib (DAS) therapy. *p<0.05, **p<0.01 
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The same kind of unresponsiveness occurred in monocytes with other stimulations as 
well. The IFN-α/IFN-δ/pSTAT1 and IL-4/pSTAT6 responses were particularly lower 
in diagnostic-phase patients compared to healthy controls, but the difference was not 
statistically significant (data not shown). This kind of unresponsiveness was not seen 
during TKI therapy.  
 
The lymphocyte fractions showed no statistically significant differences between 
healthy controls and diagnostic-phase CML patients, but interestingly, a couple of 
patients failed to respond to the IFN stimulus, as concluded from the STAT1 readout 
(Fig. 15 results from CD4+CD25+ cells). As in myeloid cell fractions, the 
lymphocyte populations responded normally to ex vivo cytokine stimulation during 
imatinib and dasatinib therapy (Fig. 15, results from CD4+CD25+ cells)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Ex vivo cytokine responsiveness of CD4+CD25+ lymphocytes of healthy 
controls, and in CML patients at diagnosis, during imatinib (IM) and dasatinib (DAS) 
therapy. 
 
 
In order to reveal the cause of this unresponsiveness to GM-CSF stimulation in 
diagnostic-phase patients, the plasma GM-CSF concentrations were measured from 
representative samples as used in the ex vivo stimulations. However the GM-CSF 
levels did not differ between the groups studied (Fig. 16).  
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Figure 16. Plasma GM-CSF concentrations in healthy controls, and in CML patients 
at the time of diagnosis (DG), during imatinib (IM) therapy and dasatinib (DAS) 
therapy. 
 
 
5.3 Automated FACS analysis software (III) 
 
The FlowAnd analysis tool was developed to overcome the increasing workload 
associated with FACS analysis. As the FACS analysis platforms have increasing 
numbers of parameters and the amount of patient material can be huge, there is an 
increasing need for automated approaches to aid in the manual gating and 
complicated data analysis. In this project, the data already analyzed with manual 
methods in project II were utilized in the development of the FlowAnd system. 
 
5.3.1 Feasibility of the FlowAnd system in FACS analysis 
 
The manually gated data were compared with software assisted gating, which was 
based on three different clustering methods: SamSpectral, flowMeans, and mixture 
modeling. The cell debris resulting from dead leukocytes and particles of lysed red 
blood cells had to be filtered out before clustering the data. This was performed by 
setting a certain threshold in the SSCXCD45 scatter, because debris sediments near 
the origin and interferes with the clustering process. One patient data set (10 FCS 
files) was used in the comparison by gating according to CD45, CD4, CD3, and CD25 
markers. An example of SSCxCD45 gating, comparing manual gating and mixture 
modeling, is presented in Figure 17.  
 
The SamSpectral and flowMeans clustering methods resulted in clusters that were 
comparable, with biologically relevant populations, while mixture modeling resulted 
in too many clusters. The correlation of the manual gating and clusteration was 
highest with SamSpectral (0.99), while the flowMeans and mixture modeling had 
correlations values of 0.69 and 0.42, respectively. The time needed for clustering was 
lowest for flowMeans (1.5h) and SamSpectral (6h). The mixture modeling required 
40h for the same analysis. Therefore, SamSpectral and flowMeans were superior to 
mixture modeling in many aspects. 
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Figure 17. Comparison of manual gating and software-assisted gating whole blood 
sample stained with CD45 antibody. A) Manual gating from SSCxCD45 plot with 
separated lymphocytes, monocytes, and granulocytes. B) Gating with FlowAnd 
software from the same sample, with a mixture modeling method. 
 
 
The performance of software-assisted gating with large-scale experiments was 
evaluated in a total of 74 FCS files from study II. In this setting, lymphocytes from 
SSCXCD45 scatter were gated and median baseline pSTAT3 values were determined. 
The clustering method used in this setting was flowMeans, which took 8.5 hours, with 
20 min of manual work. The Kruskall-Wallis statistical test incorporated into 
FlowAnd analyzed the differences between healthy controls, diagnostic-phase CML 
patients, and patients receiving either imatinib or dasatinib. This resulted in a 
significantly lower level of STAT3 phosphorylation in the dasatinib group compared 
to the healthy controls, which was the same as the result obtained with manual 
analysis (data not shown). 
 
5.4 Kinase target activation profiling (IV) 
 
In order to characterize novel markers for the imatinib therapy response, kinase target 
activation profiles of BM MNCs derived from diagnostic-phase CML patients were 
analyzed with a phosphoproteomic array, which is able to measure the activation 
status of 46 different kinase targets from the same sample. CML is associated with 
deregulated cell signaling occurring by BCR-ABL1-dependent and independent 
mechanisms and many of the kinases involved in this process could be analyzed with 
this kit.  
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5.4.1 Activation of several kinases in diagnostic CML patients 
 
The first analysis investigated the differences between healthy BM and BM affected 
with CML. All the samples were stored as snap-frozen pellets, as results from cells 
frozen with this method correlated well with fresh samples. Analysis of kinase target 
activation in healthy BM MNCs with the Proteome Profiler Human Phospho-Kinase 
Array Kit showed the highest phosphorylation levels for p53 S15, p70 S6 Kinase 
T421/S424, MSK1/2 S376/S360, GSK-3 α/β S21/S9, STAT1 Y701, TOR S2448, Akt 
T308, and RSK1/2/3 S380. However, the kinase activation profile of diagnostic CML 
patient BM MNCs differed from healthy controls, mostly due to phosphorylation of 
the p27 T157 (median ratio, CML patients/healthy controls, 3.148, p<0.05), C-Jun 
S63 (median ratio 2.194 p<0.01), Pyk2 Y402 (median ratio 2.006, p<0.05), p53 S46 
(median ratio 1.421, p<0.05), Akt T308 (median ratio 1.386, p<0.05), and AMPKα2 
T172 (median ratio 1.339, p<0.05) phosphoproteins (Fig. 18). The patient samples 
also showed higher variation between individual patients compared to the healthy 
controls (data not shown). 
 
 
Figure 18.  Differences in the phosphorylation of signaling proteins in BM MNCs 
between healthy controls and diagnostic chronic myeloid leukemia patients. *p<0.05, 
**p<0.01.  
 
 
The K562 cell line was analyzed as a positive control, resulting in highly positive 
STAT5 phosphorylation, which was expected based on the current literature 264. The 
phosphorylation was higher for the STAT5b isoform at site Y699 than for STAT5a 
Y694 (Fig. 19). However the STAT5 phosphorylation levels in CML patient BM 
MNCs were at normal levels, since comparison to healthy controls showed no 
statistically significant differences (Figs 18 G,H). Two other CML cell lines (EM-2 
and MOLM-1) were analyzed and the STAT5 activation levels were weaker than with 
K562 (data not shown). 
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Figure 19. Membrane A of the Proteome Profiler Human Phospho-Kinase Array Kit, 
representing K562 cells and BM MNCs analyzed from healthy control and diagnostic-
phase CML patients with either suboptimal (Pt#15, Table 3) or optimal (Pt#6) 
response for imatinib. Circles indicate duplicate spots representing STAT5a/b 
(Y694/Y699), STAT5b Y699, and STAT5a Y694. 
 
 
5.4.2  Suboptimal response for imatinib is connected with activation of several 
kinase targets 
 
A search for biomarkers for the suboptimal imatinib-response was performed by 
comparing BM kinase target activation profiles of diagnostic-phase patients divided 
into suboptimal and optimal response groups (Table 3). The patients in the optimal 
group were defined as achieving at least MMR after 18 months of imatinib therapy, 
while the suboptimal group achieved CCyR, but not MMR in the same time limit. 
 
Analysis revealed 15 kinase targets with significantly elevated phosphorylation levels. 
The highest difference was visible in STAT5b Y699 phosphorylation (median ratio 
>3, p<0.01, Fig. 20A), while the differences in phosphorylation of the STAT5a Y694 
isoform were not significant among the groups (Fig. 20H). The difference between 
these two STAT5 isoforms and optimal and suboptimal group are shown in Figure 19. 
 
The following six proteins had a median ratio >1.5: PLC-γ1 Y783 (p<0.05), Pyk2 
Y402 (p<0.05), Hck Y411 (p<0.05), Paxillin Y118 (p<0.05), p53 S15 (p<0.05) and 
RSK1/2/3 S380 (p<0.05) (Figs 20 B-G). Eight proteins had a median ratio below 1.5: 
RSK1/2 S221, p70 S6 Kinase T229, C-Jun S63, p53 S46, GSK-3 α/β S21/S9, Akt 
T308, p70 S6 Kinase T421/S424, and TOR S2448, while p70 S6 kinase T389 was 
significantly increased in the suboptimal group (p<0.0342), but the phosphorylation 
levels were at unreliable levels.  
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Figure 20. Comparison of BM kinase target activities in diagnostic CML patients 
divided into optimal and suboptimal response groups. *p<0.05, **p<0.01 
 
 
Patients were also analyzed according intermediate and low risk Sokal factors (Table 
3). The proteins that were statistically significant in optimal/suboptimal analysis were 
did not show statistically significant differences, but β-catenin protein expression and 
ERK1/2 T202/Y204 T185/Y187 phosphorylation were significantly (p<0.05) elevated 
in the intermediate group (data not shown). 
5.4.3 Kinase target activation related to TKI resistance 
 
Kinase activation related to TKI resistance was studied further by analyzing 
additional patients in whom TKI therapy had failed. Patient (#39) was analyzed as 
this patient carried an imatinib-resistant M351T mutation and showed no genetic 
response for imatinib, dasatinib and bosutinib. The patient had an exceptionally high 
HSP27 S78/S82 phosphorylation level (Figs 21A, B), which was not seen with any 
other CML patient or healthy control. The patient also had high STAT5b Y699 levels 
(Figure 21B).  
 
Patient #40 had achieved a minimal cytogenetic response to imatinib and nilotinib and 
patient #41 was in blast crisis during BM sampling after a short period of imatinib-
therapy. Results from these patients did not indicate high HSP27 phosphorylation, but 
their BM MNCs showed high expression of β-catenin and phosphorylation of 
ERK1/2, T202/Y204 T185 Y187, p70 S6 kinase T389, and p27 T198 (data not 
shown). 
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Figure 21. Levels HSP27 S78/S82 phosphorylation of BM from patient #39 (Table 3). 
A) Comparison of HSP27 S78/S82 between different patient groups, patient #39, and 
the K562 cell line. B) Kinase array membrane with STAT5b Y699 and HSP27 
S78/S82 highlighted. 
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6 DISCUSSION 
 
Imatinib was the first kinase inhibitor approved for clinical use and it dramatically 
changed the natural history of CML by inducing cytogenetic and molecular responses 
in a majority of patients. In the approximately 10 years since the introduction of 
imatinib, 12 small-molecule kinase inhibitors have been approved by the FDA to treat 
various types of cancer. However, experience in the clinic quickly showed emerging 
problems with resistance, mainly due to point mutations in the KD area. To overcome 
this drawback, second and third generation TKIs have been developed to treat 
imatinib-resistant and tolerant patients. Dasatinib and nilotinib have shown superior 
therapy responses in CML patients compared to imatinib, which has led to their 
approval as first line therapy modes in the USA and many European countries. 
Despite the excellent therapy responses seen with these two second generation drugs, 
persistent mutations such as T315I exist that are resistant even to dasatinib and 
nilotinib. Ponatinib is a third generation TKI specifically designed to target mutations 
resistant to second generation TKIs, including the notorious T315I mutation. 
Preliminary results from clinical trials with ponatinib have been promising. 179 
 
The clinical strategy of personalized medicine, which divides patients into 
subcategories according to certain clinical features and biomarkers in order to find 
optimal therapy modes, is evolving strongly into the field of TKIs. Experience in the 
treatment of BCR-ABL1-driven leukemias with TKIs, which spans over a decade, has 
illustrated that patients are individuals in terms of responsiveness. Extensive research 
has characterized many biomarker candidates for the imatinib response, based on 
genetic and proteomic approaches. However, although the repertoire of new TKIs is 
increasing, better characterization of patients is needed for optimal therapy selection. 
The aim of this PhD thesis was to characterize kinase activation statuses in CML 
patients, which could be connected with certain therapy responses.  
 
The first study describes a pre-B ALL patient who was resistant to conventional 
chemotherapy normally used to induce a remission of leukemia. Cytogenetic 
characterization with G-banding showed a reciprocal translocation between 
chromosomes 1 and 9. More detailed analysis revealed that the ABL1 gene had fused 
to an unknown gene. The patient received dasatinib, which had previously shown 
efficacy with Ph+ ALL patients. The dasatinib therapy, combined with methotrexate, 
rapidly resulted in CCyR and HSCT was carried out successfully. However, 12 
months after the transplantation, the patient relapsed, but re-entered into CCyR 
following dasatinib therapy, confirming the reoccurrence of the same ABL –driven 
leukemia. Dasatinib caused some adverse effects, in the form of colitis and dermatitis 
and therapy was switched to imatinib, and patient has remained in remission since. 
 
The good therapy response seen with a TKI aroused interest in the molecular 
mechanism underlying this disease. A similar case of an 11-year-old boy with pre-B 
ALL was recently described in a publication by De Braekeleer et al. The patient also 
carried a 1;9 translocation, which was shown to involve the ABL1 gene. The group 
mapped the breaking point area of chromosome 1 by BAC cloning and FISH 
methods, and identified RCSD1 as a possible fusion candidate 263. Based on this 
information, specific PCR primers were designed in our project to bind the RCSD1 
and ABL1 genes, which led to confirmation of the RCSD1-ABL1 fusion gene. The 
RCSD1 gene encodes for a CapZ-interacting protein (CapZIP), which is normally 
	   56	  
expressed in immune cells, splenocytes, and muscle and is involved in actin filament 
remodeling. 265 The mechanisms by which RCSD1 fusion to ABL induces leukemia is 
not known and it would be interesting to study whether RCSD1-ABL induces same 
kind of oncogenic signaling as is seen with BCR-ABL1. 
 
This was the first time that an RCSD1-ABL1 fusion gene was identified and confirmed 
by PCR. Most likely, the original publication suspecting RCSD1 also involved the 
same fusion gene. Also three additional cases involving RCSD1-ABL1 fusion gene 
have been reported in ALL patients.104,109,266 One of these patients was treated with 
TKIs combined with dexamethasone and was able to receive a transient response.266. 
This finding and our results indicate the possibility of treating RCSD1-ABL1 positive 
leukemias with dasatinib or other TKIs and suitability RCSD1-ABL1 as a biomarker 
for TKI therapy. 
 
The second study in this dissertation assessed immune cell function in CML patients 
at diagnosis and during TKI therapy, using single cell phosphoprotein analysis. This 
method, also called single-cell network profiling (SCNP), was originally developed 
by Garry Nolan’s group at Stanford University. This FACS based method is able to 
assess signaling pathways in heterogeneous tissues such as PB and BM. Traditionally, 
measurement of cell phosphorylation has been conducted with Western blotting 
analysis, which uses lysates and thereby mixes all cellular contents. Phosphorylation 
levels obtained in this way are an average of all cell types and information regarding 
different compartments in heterogeneous tissues is lost. The single cell 
phosphoprotein analysis method is able to combine the benefits of traditional FACS 
analysis and Western blotting in multiparameter FACS by using cell surface markers 
and antibodies against phosphorylated intracellular signaling proteins. In order to 
evoke more prominent phosphorylation patterns, signaling can be induced with 
cytokine stimulation. 267  
 
This technique has been utilized in few studies that have evaluated its performance in 
the measurement of therapy responses in leukemia. A study conducted with AML 
patients revealed a correlation between therapy response for induction-chemotherapy 
and certain signaling patterns. The same study demonstrated reproducibility of the 
data obtained with single cell phosphoprotein analysis and emphasized its usefulness 
as a method for the discovery of novel prognostic factors for AML therapy responses. 
268 A similar approach, also conducted with AML patients treated with valproic acid, 
all-trans retinoic acid, and theophylline, was able to cluster patients according to 
signaling activity that correlated with therapy responses.269 
 
This is the first time that this method has been used to study immunity of CML 
patients. Controversy has surrounded the effects of TKI therapy on the immune cell 
function. The off-target inhibitory activity of TKIs affects many kinases involved in 
immune responses. Imatinib and dasatinib can inhibit T cell function in vitro 270-272.  
On other hand, in the clinical trials assessing safety of TKI therapy, no remarkable 
occurrence of opportunistic infections have been observed, which argues against 
immunosuppressive effect of TKIs. 
 
Different cytokines essential for regulating the immune system were used to stimulate 
intracellular signaling in fresh blood samples obtained from healthy controls, 
untreated diagnostic –phase CML patients, and patients treated either with imatinib or 
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dasatinib. The measurement of phosphoproteins STAT1, STAT3, STAT5a, STAT6, 
and ERK1/2 in different cell populations was made possible with multiparameter 
FACS. One major finding was that myeloid cells of diagnostic-phase patients are 
unresponsive to GM-CSF stimulation, which was reversed during TKI therapy. This 
was not explained by plasma GM-CSF levels. Deficient GM-CSF receptor function in 
malignant myeloid cells could explain the weak responses 273 and would implicate 
autonomy of leukemic cells. In general, no significant differences were noted between 
the healthy controls and CML patients treated with TKIs with respect to their 
phosphoprotein responses. This finding further argues against an immunosuppressive 
role of TKIs in CML patients. 
 
The basal phosphorylation levels did not differ between healthy controls, or 
diagnostic phase and imatinib-treated CML patients in any of the cell populations 
analyzed. Dasatinib treatment was associated with low phosphorylation levels of the 
studied signaling proteins, particularly STAT3, which was significantly decreased 
compared to the healthy controls in both lymphoid and myeloid cell compartments. 
Although STAT3 is not a direct target of dasatinib, but transient dasatinib mediated 
STAT3 inhibition was noted in a study conducted with solid tumor cell lines and was 
likely mediated via SRC family kinase inhibition.274 STAT3 has many cellular 
functions, and one of them is promotion of oncogenesis by upregulating expression of 
genes essential for survival, proliferation, angiogenesis, and metastasis. Another 
cancer promoting effect is suppression of tumor immunity by STAT3. 275 Inhibition 
STAT3 phosphorylation in dasatinib-treated patients might thus reinforce the anti-
tumor immunity. 
 
The purpose of study III was to develop a tool for automated FACS data analysis  that 
would facilitate the laborious manual work. Multiparameter flow cytometry is now 
routinely used in clinical laboratories for diagnostic and disease follow-up purposes. 
Despite the technical improvements made in the last few years to increase the 
throughput of FACS instrumentation, the data analysis platforms have not reached 
their full potential. Data analysis is the most challenging and time-consuming step in 
flow cytometry and it is also a major source of variance among clinical tests 276. 
Gating has traditionally been based on the personal intuition of the analyzing person 
and has lacked standardization. Manual gating also has limitations with the two-
dimensional analysis setting. Automated approaches can process the data 
multidimensionally, thereby gaining novel information and also diminishing variation 
caused by manual gating. 
 
The FlowAnd FACS analysis tool performed the full range of FACS data analysis and 
the results were comparable to those achieved by manual work. However, the FACS 
immunostainings analyzed this way were rather simple, and further development is 
needed to handle the current demanding routine analysis platforms. Previous similar 
approaches, such as FLAME 262, FIND 277, and flowCore259, have been published 
before. However, FLAME was unable to handle the amount of data that existed in our 
study II data files. FlowAnd has a more diverse set of analysis tools than does FIND 
and it turned out to be more user friendly than flowCore. 
 
Study IV continued with analysis of cell signaling associated with CML, with the aim 
of finding novel prognostic factors that could predict a response to imatinib at the 
time of diagnosis. MMR is considered as the therapy target in newly diagnosed CML 
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patients. This should be achieved within 18 months, in order to have an optimal 
treatment response. 233 It would useful to be able to predict the therapy response 
earlier, as there are different options regarding the TKIs available. Traditional clinical 
factors like Sokal, Hasford, and EUTOS are not able to provide an optimal prediction 
of the response to imatinib, and since research has identified many potential 
biological biomarkers, more effort is needed in this field.  
 
Comparison of kinase activities of BM MNCs from diagnostic phase patients, divided 
into optimal and suboptimal groups according to their responses to imatinib, revealed 
elevation of several phosphoproteins associated with poorer outcome. The most 
marked difference between these groups was seen in STAT5b phosphorylation. The 
CML cell lines were analyzed as well, and showed highly different kinase activation 
patterns compared to patients’ material, which points to the importance of using 
primary cells as research material.  
 
The high variety of STAT5 phosphorylation levels seen in patient material was 
surprising because STAT5 is regarded as one of the main proteins mediating the 
BCR-ABL1 signaling cascade. This activation has been clearly demonstrated in many 
studies utilizing cell lines. 82,264 One of the most common experimental models used 
in CML research is the K562 cell line, which showed extremely high STAT5b 
phosphorylation, in our studies. The K562 line is derived from a blast crisis patient, 
who also had additional chromosomal changes, 278 so that this cell line probably does 
not reflect the situation in chronic phase CML patients. Studies conducted with 
patient samples indicate that STAT5 activation is associated with advanced phases of 
the disease. 279,280 The conclusion from these results is that STAT5 activation, and 
especially that of the STAT5b isoform, is linked to disease progression and may 
predict a poorer outcome at the time of diagnosis of chronic phase patients. In 
addition, three patients in the present study, who had failed with different modes of 
TKI therapy, showed signaling patterns that were not seen in imatinib-responsive 
patients, which could implicate further BCR-ABL1-independent survival 
mechanisms.  
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7 CONCLUSIONS 
 
This thesis characterizes a novel RCSD1-ABL1 fusion gene in an ALL patient that 
results from a translocation between chromosomes 1 and 9. The patient responded 
well to dasatinib, which is normally used in the treatment of BCR-ABL1 positive 
leukemias. These findings provide evidence that the indicated leukemia is caused by 
aberrant ABL1 kinase activity resulting from fusion to RCSD1, although the precise 
molecular mechanism is unknown. Despite only five ALL patient cases have been 
reported with the specific genetic abnormality, the findings serve a broader 
implication as they provide a novel tool for identification of ALL patients who will be 
responsive to dasatinib. This also gives emphasis on the importance of dividing 
patients into subcategories according to their genetic background for optimal therapy 
selection.  
 
In addition to the RCSD1-ABL1 fusion gene, this thesis also argues against an 
immunosuppressive role of TKIs in CML patients, as the responsiveness to various ex 
vivo cytokine stimulations remained at normal levels, as revealed by single cell 
phosphoprotein analysis of imatinib- and dasatinib-treated patients. However, the goal 
of connecting distinct signaling patterns to therapy responses was not achieved with 
this method. Myeloid cells of diagnostic-phase patients were found unresponsive to 
GM-CSF stimulation despite the fact that plasma levels of this growth factor were at 
normal levels. The findings may indicate an autonomous role of Ph+ leukemic cells in 
untreated CML patients, since phosphoprotein responses to GM-CSF stimulation 
were normalized with TKI therapy. The basal STAT3 phosphorylation levels were 
diminished in patients treated with dasatinib in all cell compartments and could be 
connected with dasatinib-induced anti-tumor immunity. The laborious FACS data 
analysis performed with this single cell phosphoprotein method led to the 
development of an automated FACS analysis program. This is likely a prototype for 
future automated FACS analysis programs needed to facilitate the arduous manual 
work. 
 
Prognostic factors connected to certain imatinib therapy responses were searched 
from BM signaling activities in diagnostic phase CML patients. The 
phosphoproteomic approach was able to identify multiple signaling proteins that were 
associated with poorer outcome. The main phosphoprotein detected in this way was 
STAT5b, which has been shown to contribute to disease progression in CML. 
 
This doctoral thesis provides novel information about different biological prognostic 
factors related to TKI therapy responses in the treatment of CML and particular Ph 
negative ALL. The findings can possibly be utilized in the future in clinical 
applications such as optimal therapy selection, risk assessment and the measurement 
of TKI therapy responses. 
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